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Do patients with methicillin-resistant Staphyloccus aureus (MRSA) infections of the skin revert
to methicillin-susceptible isolates?
A Patel, E Hill, E Simpson and J Hanifin Oregon Health and Science University, Portland, OR
Our clinical observations from patients with atopic dermatitis have suggested that a significant num-
ber of MRSA infections revert to methicillin-susceptible S. aureus (MSSA) after therapy. This led us
to perform a retrospective review of patients with MRSA skin or soft tissue infections in our institu-
tional database. Culture records were reviewed, and patients were included if they had an initial
positive culture for MRSA from a skin or soft tissue site and had subsequent culture results from a
separate site or the same site at least one month apart in an attempt to exclude repeat culturing of
the same infection. After reviewing 1496 culture records, 210 patients met these criteria. Ten patients
had incomplete chart records and were excluded. Among the 200 patients analyzed, we found that
60 (30%) showed reversion to MSSA on at least one occasion. Ten of these patients’ cultures alter-
nated between MRSA and MSSA. Among the 50 subjects (25%) who remained MSSA positive, we
examined factors typically associated with persistent, recurrent, and increased frequencies of MRSA
infections. Our data showed a trend toward persistent MRSA positivity in patients on immunosup-
pressive medications (RR 1.8, 95%CI [0.66 - 5.1]) or on antibiotics within 1 week of the first cul-
ture (RR 1.9, 95%CI [0.87- 4.3]). Because of the small sample size, p values were not statistically
significant. Use of intravenous drugs, presence of invasive devices, and diagnoses of diabetes mel-
litus or HIV did not correlate with MRSA persistence. Of the 6 patients with atopic dermatitis, four
had dermatitis flares associated with S. aureus infections, and two reverted to MSSA, which is con-
sistent with our overall findings. This study highlights the significant number of patients who revert
to MSSA after MRSA infections, and, presumably, clear their MRSA colonization. This information
has not previously been reported, and will hopefully impact physician practices in the use of post-
MRSA cultures and the choice of antibiotics available for treatment.
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Associated comorbidities in patients with vitiligo and alopecia areata
EX Wei-Passanese,1 V Sheth,2 KP Huang2 and AA Qureshi2 1 Harvard Medical School, Boston,
MA and 2 Dermatology, Brigham and Women’s Hospital, Boston, MA
Vitiligo is a pigmentary disorder characterized by loss of melanocytes in the affected skin. Alope-
cia areata (AA) is an autoimmune disease that results in nonscarring hair loss. Although an associ-
ation between vitiligo and AA has been described, characterization of patients affected by both dis-
eases has been limited. The present study is a multi-center, retrospective review comparing gender,
age of onset, race, education level, and associated comorbidities in patients with documented vitiligo
and AA. In this population, 2976 patients had the diagnosis of vitiligo and 3376 patients had the
diagnosis of AA. Among these, there were 81 patients with both diagnoses; we limited this study
individuals with dermatologist-documented diagnoses of vitiligo and AA (n = 45). We found no gen-
der predilection in this population. Vitiligo development preceded AA in 66% of the cases. The aver-
age age of diagnosis of either vitiligo or AA was 33 years, with 25% of the individuals diagnosed
prior to age 20 years and 64% diagnosed prior to age 40 years. Fifty-three percent of this group was
Caucasian, and 38% was Hispanic. Seventy-five percent were current non-smokers and 62% of the
population had never smoked. Eighty-two percent of these patients had associated comorbidities
with an average age of 43 years at the time of data collection. The most common comorbidity in
this population was obesity (40%), followed by thyroid dysfunction (27%) and eczema (24%). The
rate of sexual dysfunction, menstrual irregularities, and infertility was 18%. Other autoimmune
skin diseases were also common in this population, including psoriasis (9%) and systemic lupus
erythematosus (9%). Approximately 9% of the population suffered from depression. Overall, we
observed an ethnic predilection and a high rate of comorbidities in this population. These findings
differed from what is commonly observed in either disease alone. The pathophysiology leading to
the high rate of comorbidities is unclear, but genetic and psychosocial factors may play a role.
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Treatment satisfaction with commonly used treatments for moderate to severe plaque psori-
asis in clinical practice
H Yeung*,1 K Callis Duffin*,2 J Wan,1 AB Troxel,1 DB Shin1 and JM Gelfand1 1 Department of
Dermatology, University of Pennsylvania, Philadelphia, PA and 2 Department of Dermatology,
University of Utah, Salt Lake City, UT
Previous studies using ad hoc instruments showed that many patients with psoriasis are dissatisfied
with treatments. With important implications on medical decision-making, treatment adherence
and success, treatment satisfaction must be assessed rigorously to address the gap between treat-
ment efficacy in clinical trials and effectiveness in clinical practice. 700 patients with plaque pso-
riasis currently receiving methotrexate, adalimumab, etanercept, ustekinumab, or narrowband UVB
phototherapy were surveyed in 10 sites across the U.S. (response rate 95%) using the Treatment Sat-
isfaction Questionnaire for Medication version II (TSQM). It is a psychometrically validated instru-
ment shown to predict medication persistence and dosing adherence. Median scores (IQR) of the
Effectiveness, Side Effects, Convenience, and Overall Satisfaction subscales in the TSQM were 83.3
(58.3-91.7), 100 (100-100), 77.8 (66.7-83.3), and 83.3 (66.7-91.7), respectively. In the fully adjusted
model, patients receiving adalimumab (β = 5.8 points, 95% CI 3.2-8.4), etanercept (5.8, 95% CI
3.3-8.3), ustekinumab (6.5, 95% CI 3.3-9.8), and narrowband UVB (6.5, 95% CI 3.5-9.5) reported
higher median Overall Satisfaction scores than patients receiving methotrexate. Median Effective-
ness scores were the lowest for methotrexate, whereas median Convenience scores were the low-
est for phototherapy. Overall satisfaction correlated weakly with the Psoriasis Area and Severity
Index (ρ = -0.32) and moderately with the Dermatology Life Quality Index (ρ = -0.43). In this first
study to examine psoriasis treatment satisfaction using a validated instrument, we observed gener-
ally high levels of satisfaction with commonly used treatments for moderate to severe psoriasis.
Small but discernable differences were found in satisfaction with Effectiveness and Convenience.
Further application of treatment satisfaction measures may inform patient-centered treatment deci-
sions and guideline development.
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Trends of in situ melanoma in U.S. men and women
EX Wei-Passanese,1 J Han,2,3,4 JY Lin2 and AA Qureshi2 1 Harvard Medical School, Boston, MA,
2 Department of Dermatology, Brigham and Women’s Hospital, Boston, MA, 3 Channing
Laboratory, Brigham and Women’s Hospital, Boston, MA and 4 Department of Epidemiology,
Harvard School of Public Health, Boston, MA
Melanoma is the fastest growing cancer in the US and worldwide. There have been limited studies
in literature assessing the epidemiology of in situ melanoma in the US. The authors investigated the
trends in diagnosis, body site of occurrence, and pathological sub-types of in situ melanoma in two
national prospective cohorts: Nurses’ Health Study I (1976-2004) and Health Professionals Follow-
up Study (1986-2004). From 1977 to 2004, the ratio of in situ to invasive melanoma increased 15-
fold (from 0.09 to 1.32). The incidence rate of non-specific pathological subtype exceeded that of
lentigo maligna. In situ lesions were equally likely to be found on the head/neck, trunk, upper and
lower extremities of women, but favored the head/neck and trunk of men. The body area most sus-
ceptible to development of in situ melanoma did not change over time. Melanomas (invasive and
in situ) that developed at a younger age tend to favor areas of intermittent sun exposure, whereas
those that develop in older individuals tend to favor areas of chronic sun exposure. Together these
findings are suggestive that the increase in in situ melanoma may be due to a true increase in the
development of in situ lesions, improved screening techniques over the past 20-years, but are also
likely to be in part, due to lower threshold for diagnosing due to medicolegal pressure.
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Difficulty in dermatologists reporting melanoma to state cancer registries
LC Payne2 and S Chen1,3 1 Dermatology, Emory University, Atlanta, GA, 2 Morehouse School
of Medicine, Atlanta, GA and 3 Atlanta VAMC, Atlanta, GA
Melanoma is a unique cancer in that many cases, especially early stages, are treated in the outpa-
tient setting, bypassing any interaction with a hospital or pathology lab. While this allows for con-
venient treatment for patients, it also allows for the possibility of melanoma to go unreported to can-
cer registries. By law, every new melanoma case is mandated to be reported to each state cancer
registry by a hospital facility, pathology lab, or dermatologist. The purpose of this study was to iden-
tify the various ways in which each state’s cancer registry allows and advocates individual derma-
tologists to report new melanoma cases. A three-question survey was administered to each state reg-
istry regarding (1) available electronic reporting methods, (2) online downloadable forms, and (3)
the acceptance of paper pathology reports from dermatologists. Out of the 49 states who partici-
pated, 43 state registries allowed dermatologists to submit paper pathology reports for new melanoma
cases, but only 31 allowed some type of electronic reporting (either online and/or access to an online
reporting form returned by mail or fax.) With the increasing incidence of new melanoma cases,
along with evolving trend of clinical practice towards electronic medical records, providing der-
matologists with a fully electronic method of reporting new melanoma cases to their state cancer
registry might allow for better reporting and accounting of diagnosed melanoma cases nationwide.
In turn, these more accurate statistics of the epidemiology of melanoma will allow for the proper
allocation of funds for future melanoma education and research.
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Risk of second primary malignancies after dermatofibrosarcoma protuberans
DE Kurlander,1 KJ Martires1 and JS Bordeaux2,1 1 Case Western Reserve University School of
Medicine, Cleveland, OH and 2 Dermatology, University Hospitals Case Medical Center,
Cleveland, OH
The risk of primary malignancies following dermatofibrosarcoma protuberans (DFSP) is unknown.
Using the Surveillance, Epidemiology, and End Results (SEER) database (1973-2008), we examined
the risk of developing subsequent primary malignancies in 3,749 DFSP patients. Patients diagnosed
with DFSP had an overall increased risk of subsequent primary malignancies compared with the
general population (observed/expected (O-E), 1.25; 95% CI, 1.13-1.37). Specifically, they were at
increased risk for other non-epithelial skin cancer (O-E, 21.60; 95% CI, 13.84-32.14), soft tissue
cancer (O-E, 4.89, 95% CI, 2.24-9.28), melanoma of the skin (O-E, 1.90; 95% CI, 1.22-2.83), and
female breast cancer (O-E, 1.44; 95% CI, 1.13-1.80). Females with DFSP were also at increased
risk of kidney cancer (O-E, 2.61; 95% CI, 1.13-5.14) and decreased risk of colon cancer (O-E, 0.24;
95% CI, .05-.71). Males with DFSP were not at increased risk for melanoma, but were at increased
risk of chronic lymphocytic leukemia (O-E, 3.03; 95% CI, 1.01-6.60). Patients with DFSP are at an
overall increased risk for a number of subsequent primary malignancies. Knowledge of this risk is
important for surveillance after diagnosis and treatment.
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Dramatically improved overall survival and predictors of disease in 17 metastatic basal cell
carcinoma patients
C Danial, B Lingala, AE Oro and AS Chang Dermatology, Stanford University School of
Medicine, Redwood City, CA
Metastatic basal cell carcinomas are rare epithelial cancers whose clinical course is not well char-
acterized. Overall survival (OS) rate in metastatic basal cell carcinoma (mBCC) has been reported
at 10-14 months based on several case series and in the last major retrospective study performed
in 1980. The purpose of our study is to provide an updated OS rate along with disease predictors
of mBCC from a single academic center. Electronic medical records from the Stanford University
Cancer Center Database of 49 consecutive patients aged 19-90 years from 1998-2011 with mBCC
(n=17, Stage IV) or locally advanced BCC(defined as BCC incurable with surgical means alone,
includes Stages I-III)(n=32) were reviewed. OS was calculated by Kaplan-Meier analysis and haz-
ard ratios were generated for predictors of metastatic disease. This study included 36 males and 13
females; 8 had Gorlin’s syndrome (only 1 mBCC patient with Gorlin’s syndrome). The most com-
mon sites of metastases were pulmonary (11/17 patients), osseus (8/17 patients) and distant lymph
nodes (2/17 patients). The median OS rate for mBCC from the time of metastatic diagnosis was 9.8
years (includes n=6 all-cause deaths, n=11 ongoing survivors). The mean OS rate for locally advanced
BCC was 10.1 years. Hazard ratios for diagnosis of mBCC included: basosquamous subtype 6.34,
95% C. I. [2.72-14.75], current alcohol use 3.15, 95% C. I. [1.1-9.0], and age 1.04 [1.01-1.07].
Hazard ratio for mBCC of infiltrative subtype was 0.18, [0.06-0.52] with 16 locally advanced and
4 mBCC with this subtype. Current or history of smoking and gender were not significant predic-
tors of mBCC. The patients in this study received multiple modalities including surgery (n=41), radi-
ation (n=29), Smoothened inhibitors (n=30), other chemotherapies (n=12), and alternative treat-
ments (n=2). In our study of the largest mBCC cohort, the overall survival was significantly longer
than previously reported. The optimal treatment regimens remain to be determined. Future studies
may reveal which treatments prolong survival.
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Limitations of psoriatic arthritis screening instruments in patients with psoriasis
JA Walsh,1 K Callis Duffin,2 G Krueger2 and DO Clegg1 1 Division of Rheumatology, University
of Utah, Salt Lake City, UT and 2 Dermatology, University of Utah, Salt Lake City, UT
We compared the abilities of 3 screening instruments to predict the diagnosis of psoriatic arthritis
(PsA) in patients with psoriasis. In a prospective cross sectional study, 213 participants of the Utah
Psoriasis Initiative completed the Psoriasis Epidemiology Screening projecT (PEST), Toronto Psori-
atic Arthritis Screen (ToPAS), and Psoriatic Arthritis Screening and Evaluation (PASE) prior to rheuma-
tologic evaluation. Sensitivities and specificities were determined by comparing instrument out-
comes to diagnostic assessments of a board certified rheumatologist (JAW). Disease features were
compared in patients with positive and negative instrument outcomes with Student’s t-tests and
Fisher’s exact tests. Physical examination findings were compared to question responses with Fisher’s
exact tests. The sensitivities of PEST, ToPAS, and PASE were 0.85, 0.75, and 0.68, and the specifici-
ties were 0.45, 0.55, and 0.50, respectively. Higher disease activity, as measured by the Psoriatic
Arthritis Quality of Life score (p < 0.001- 0.05) and the number of PsA features (p < 0.001 -0.12),
associated with positive instrument outcomes in patients with and without PsA. Dactylitis associ-
ated with positive instrument outcomes in PsA patients (p = 0.002 - 0.005) and was not seen in
patients without PsA. Agreement between examination data and questions about peripheral arthri-
tis was lower for ToPAS than PEST (p <0.001) and PASE (p <0.001). In conclusion, the 3 screening
instruments had lower sensitivities and specificities in this population, compared to the popula-
tions in which they were developed. This population was enriched with patients with PsA and other
types of musculoskeletal disease and may represent patients who are most likely to complete a
screening instrument and follow through with a rheumatology referral. Further analyses may iden-
tify the most effective questions from each instrument and lead to the development of successful
screening strategies for PsA in psoriasis patients with musculoskeletal complaints.
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Monkey see, monkey do: Contagious itch in nonhuman primates
AN Feneran,1 R O’Donnell,2 A Press,2 G Yosipovitch,1,3,4 M Cline,2 G Dugan,2 A Papoiu,1
L Nattkemper,1,3 Y Chan5 and CA Shively2 1 Dermatology, Wake Forest School of Medicine,
Winston-Salem, NC, 2 Pathology/Comparative Medicine, Wake Forest School of Medicine,
Winston-Salem, NC, 3 Neurobiology & Anatomy, Wake Forest School of Medicine, Winston-
Salem, NC, 4 Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC
and 5 Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore,
Singapore, Singapore
Itch is a common problem in humans and nonhuman primates. Contagious itch has been anecdo-
tally reported and recently confirmed in a controlled setting in humans. It has been postulated that
the origin of contagious itch in humans can be traced to earlier primates. Here, we investigate in
adult rhesus macaques whether ‘contagious itch’ occurs spontaneously in monkeys. In the first exper-
iment, latency to scratch following cagemate scratching was observed in 16 pair-housed adult rhe-
sus macaques. Scratching peaked within the first 60 seconds after cagemate scratching and subse-
quently declined. In the second experiment, individually caged adult rhesus macaques were shown
a video sequence consisting of other monkeys scratching, neutral visual stimuli and monkeys that
were not scratching, and scratching behavior was recorded. A contagious effect of scratching was
observed amongst cagemates. In the second experiment, a greater frequency of scratching was
observed when monkeys viewed a video sequence of another monkey scratching as well as during
the neutral stimulus immediately following the monkey scratching. Viewing other monkeys scratch-
ing significantly increased scratching behavior in adult rhesus macaques.
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Factors related to the impact of pruritus on quality of life
C Carr,1 E Veledar1 and S Chen1,2 1 Emory University, Atlanta, GA and 2 Atlanta VA Medical
Center, Atlanta, GA
Pruritus is a common symptom that plagues many people, but the impact of pruritus on quality of
life (QoL) remains poorly studied. To remedy this knowledge void, we undertook a national survey
of randomly-selected patients of the Veterans Hospital system. Of the patients found to suffer from
pruritus, 405 subjects were asked questions related to demographics, medical history, therapeutics,
and the impact of pruritus on their QoL utilizing the validated, pruritus-specific ItchyQol instrument.
We investigated the relationship of various patient and treatment characteristics to the degree of
pruritus impact by looking for significant differences in mean ItchyQoL scores (I) using ANOVA and
t-tests. Several patient characteristics demonstrate significant relationships, pointing to risk factors
that are associated with a greater impact of pruritus on QoL: 1) Employment status (p <0.0001). The
unemployed (I=63) and disabled (I=61) suffer disproportionately from pruritus when compared to
the employed (I=53) and retired (I=49). 2) Race (p<0.0001). Caucasians (I=51) are less affected by
pruritus than African-Americans (I=62) and other races (I=60). 3) Marital status (p=0.014). Pruritus
has less impact on the married (I=52) vs. unmarried (I=56). 4) Use of prescription topical, over-the-
counter (OTC) oral, and prescription oral medications to control itch (p ≤0.0009). Patients whose
pruritus exerts a greater QoL impact are more likely to use these medications (58≤I≤62) than not
(50≤I≤52). No such significant relationship exists for OTC topical medications (p=0.14). Other patient
characteristics did not demonstrate significant relationships with the ItchyQoL scores, specifically,
gender (p=0.20), income (p=0.13), and education (p=0.073). Pruritus unequivocally causes an
adverse effect on QoL. The results outlined above provide initial insight into risk factors associated
with a greater impact of pruritus on QoL. These findings represent an initial step in deciphering the
variables that determine the degree of impact that pruritus has on QoL.
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Comparative effectiveness of commonly used systemic treatments or phototherapy for mod-
erate to severe plaque psoriasis in clinical practice
JM Gelfand,1 J Wan,1 GG Krueger,2 K Callis Duffin2 and AS Van Voorhees1 1 U. of Pennsylvania,
Philadelphia, PA and 2 U. of Utah, Salt Lake City, UT
Despite a few short-term comparative trials of oral systemic and biologic agents for psoriasis, there
are no data assessing the effectiveness of such therapies in real world practice, a critical and rec-
ognized data gap. The purpose of this multi-center study was to describe and compare the effec-
tiveness of commonly used systemic and phototherapy treatments for moderate to severe psoriasis
in patients being evaluated under routine care. We conducted a cross-sectional survey of 713 patients
with plaque psoriasis currently receiving methotrexate, adalimumab, etanercept, ustekinumab, or
narrowband UVB (NB-UVB) phototherapy (95% response rate) at 10 centers across the U.S. The
proportion of patients clear or almost clear on the Physician Global Assessment differed among
treatments: methotrexate (23.8%), adalimumab (47.7%), etanercept (34.2%), ustekinumab (36.1%),
NB-UVB (27.6%) (p<0.001). In adjusted analyses, patients on adalimumab (relative response rate
2.15, 95% confidence interval (CI) 1.6-2.9), etanercept (1.45, 95% CI 1.1-2.0), and ustekinumab
(1.57, 95% CI 1.1-2.3) were more likely to have clear or almost clear skin versus patients on methotrex-
ate, while patients receiving NB-UVB showed no significant difference (1.35, 95% CI 0.9-2.0)
compared to methotrexate. However, no response difference was observed with respect to quality
of life. 36% of etanercept and 12% of adalimumab patients received double the recommended
doses, while only 11% of phototherapy patients received the recommended treatment frequency.
These results suggest that the effectiveness of psoriasis therapies in clinical practice may be lower
than previously reported in trials, and dosing of common therapies varied from trial recommenda-
tions. Although relative differences in objective response rates among therapies may exist, absolute
differences are small and may not be clinically significant. These findings provide novel benchmarks
emphasizing the critical importance of studying effectiveness in real world practice.
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Validation of a large population-based basal cell carcinoma registry
MM Asgari,1 M Eide,2 M Warton,1 M Sadler1 and S Fletcher3 1 Kaiser Permanente, Oakland, CA,
2 Henry Ford, Detroit, MI and 3 Harvard Medical School and Harvard Pilgrim Health Care
Institute, Boston, MA
The epidemiology of basal cell carcinomas (BCC) is difficult to study partly because large cancer
registries exclude it and there is no unique diagnosis code. To create and validate a large BCC reg-
istry at Kaiser Permanente Northern California (KPNC), an integrated healthcare delivery system.
Using electronically assigned Systemized Nomenclature of Medicine (SNOMED) codes and text-
string searches of electronic pathology reports, we identified all electronic pathology records for
KPNC members diagnosed with a BCC in 2005 (n= 39,026). All pathology records were reviewed
by a board-certified dermatologist and assigned case/non-case status. A subset of the records (n=9,428)
were independently reviewed by a second dermatologist to ascertain reliability of case assignment.
Using manually reviewed pathology case assignment as the gold standard, we calculated the sen-
sitivity and specificity of three slightly different algorithms for identifying BCCs directly from elec-
tronic pathology data. BCC-specific SNOMED codes had a sensitivity of 96.9% (95% confidence
interval (CI): 0.96.7-97.1) and a specificity of 98.5% (95% CI: 98.3-98.7) in identifying BCCs. Inter-
rater reliability for case assignment was high (kappa=0.92, 95% CI: 0.91-0.93). The data are lim-
ited to one health care setting and inter-rater reliability was performed on only a subset of the cohort.
We did not distinguish between incident and recurrent BCCs. We created and validated a large reg-
istry which can serve as a unique resource for studying BCCs.
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Melanoma screening can substantially reduce melanoma mortality: Evidence from the SCREEN
project in Schleswig-Holstein
A Katalinic,2 A Waldmann,2 MA Weinstock,1 A Geller,3 N Eisemann,2 R Greinert,4 B Volkmer4 and
E Brietbart4 1 VAMC/Brown Univ, Providence, RI, 2 Institute of Clinical Epidemiology, Luebeck,
Germany, 3 Harvard School of Public Health, Boston, MA and 4 Centre of Dermatology,
Buxtehude, Germany
Influential groups in primary care have not endorsed screening for melanoma due to inadequate
evidence. We present key evidence from the seminal population-based SCREEN project conducted
in Schleswig-Holstein, Germany (SH; population 2.8 million), July 2003 – June 2004. SCREEN
involved training of 1673 of 2614 SH primary care physicians and 116 of 118 SH dermatologists
in full body skin examination for early detection of skin cancer, and employed multiple methods to
recruit SH residents 20+ years of age to be screened by these physicians. We compared melanoma
age-adjusted mortality trends in SH before and after SCREEN to adjacent comparison states with-
out SCREEN. 19% of the eligible population in SH was screened (10% of men, 27% of women),
and the screening accounted for 50% of the melanomas diagnosed in SH that year. Melanoma
mortality in SH declined 47% in men and 49% in women when comparing 5 years prior to 5 years
after the SCREEN year. This sharp drop in mortality was significant on its own and differed signifi-
cantly from the corresponding and stable trends in each of the 4 adjacent states north, east, south,
and west (Denmark, Mecklenburg-Vorpommern, Hamburg, and Lower Saxony) during this same
time period. The incidence of melanoma in SH increased during SCREEN and fell subsequently.
Additional measures, such as thickness-specific incidence rates, are not yet available. These data
do not clearly distinguish the effects of the screening examinations themselves from the those of the
associated publicity, awareness, and professional and public education. These population-based
data provide the strongest evidence to date that screening for melanoma can save lives, and in the
absence of randomized trials but combined with other published evidence, justify implementation
of melanoma screening programs in at-risk populations worldwide.
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Smoking and risk of skin cancer: A prospective analysis and a meta-analysis
F Song,1 AA Qureshi,1 X Gao,2 T Li1 and J Han1 1 Brigham and Women’s Hospital, Boston, MA
and 2 Department of Public Health, Boston, MA
The association between smoking and the risk of skin cancer has not been well established. In two
large cohorts in the US, we prospectively examined the risks of melanoma, BCC, and SCC among
participants grouped according to smoking variables. Among men, compared to never smokers,
ever smokers had a significantly lower risk of melanoma (RR = 0.72; 95% CI: 0.58, 0.86), those
who smoked 30 years or more had a RR of 0.65 (95% CI: 0.48, 0.89) (P trend = 0.003), those who
smoked fifteen cigarettes or more per day had a RR of 0.32 (95% CI: 0.13, 0.78) (P trend = 0.006),
and those who smoked more than 45 pack-years had a RR of 0.66 (95% CI: 0.45, 0.97) (P trend =
0.03). Ever smokers also had a slightly lower risk of BCC (RR = 0.94; 95% CI: 0.90, 0.98). There
was no significant association for SCC (RR = 0.99, 95% CI: 0.89, 1.12). In women, no significant
association was found for melanoma (RR = 0.96, 95% CI: 0.83, 1.10). Compared to never smok-
ers, ever smokers had a slightly higher risk of BCC (RR = 1.06; 95% CI: 1.03, 1.08) and a higher
risk of SCC (RR = 1.19; 95% CI: 1.08, 1.31). A significantly inverse association between smoking
and melanoma was only limited to the head and neck (RR = 0.65; 95% CI: 0.42, 0.89). Smoking
was inversely associated with melanoma risk, especially on the head and neck. Further studies are
warranted to investigate the underlying mechanism.
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Dermatologists and popular media may influence the social acceptability of handheld umbrel-
las for sun protection
J Ezirike,3 J McMichael,1 J Rice,1 E Veledar1 and SC Chen1,2 1 Emory University, Atlanta, GA, 2
Atlanta VAMC, Atlanta, GA and 3 Morehouse School of Medicine, Atlanta, GA
Handheld umbrella (HU) use is a popular method of sun protection in some regions of the world.
We sought to assess the social acceptability (SA) of HU use among women in the United States.
From August to December 2011, a 3-part survey was administered to 182 community and univer-
sity-affiliated women in Atlanta, Georgia. In Part 1, participants were asked if they had used a HU
for sun protection in the past year and to rate how socially acceptable they deemed HU use. Based
on responses to Part 1, Part 2A or 2B ascertained reasons for using or not using a HU. Participants
viewed a collage of famous women with HUs before Part 3, which reassessed their rating of the SA
of HU use and the possibility of HU use in the future. Paired t-tests were used to compare pre- and
post-collage ratings of SA. 69% of participants were White, 19% were Black/ African-American, and
6% were Asian. The mean age (SD) was 26 (10) years. The prevalence of HU use was 8%. 30% of
Asian, 15% of Black, and 3% of White participants reported HU use. Only 3 of 20 who reported
having photosensitive skin diseases confirmed HU use. The top reason for using a HU was avoid-
ance of wrinkles. One of the top reasons for not using a HU was “just never thought about using
one.” Of those who denied HU use, 71% answered maybe or yes to considering HU use if recom-
mended by a dermatologist and 76% answered maybe or yes to considering HU use if more peo-
ple did so. The mean pre-collage rating of the SA of HU was 4.89 (1 = not socially acceptable at
all, and 10 = totally socially acceptable) compared to 5.33 post-collage (mean difference -0.44
(1.22), p=<.0001). Dermatologists’ recommendations, popular media, and public practices may
play a significant role in whether women view HU use as a socially acceptable form of sun pro-
tection. Dermatologists may consider including HU use in their sun protection discussions with
female patients.
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Aspirin is associated with lower melanoma risk in a cohort of postmenopausal women in the
Women’s Health Initiative (WHI)
SM Swetter,1,2 CA Gamba,2 ML Stefanick,2 KM Spaunhurst,3 J Kubo,2 M Desai,2 MM Asgari,4
AA Sinha5 and JY Tang2 1 VA Palo Alto Health Care System, Palo Alto, CA, 2 Stanford University
School of Medicine, Stanford, CA, 3 University of Southern California Keck School of
Medicine, Los Angeles, CA, 4 Division of Research, Kaiser Permanente Northern California,
Oakland, CA and 5 Department of Dermatology, University at Buffalo and Roswell Park
Cancer Institute, Buffalo, NY
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with decreased risk of gas-
tric, colorectal, and breast cancer. Evidence from observational studies investigating the associa-
tion between NSAID use and risk of melanoma has been inconsistent. We evaluated the associa-
tion between NSAID use and risk of melanoma in 70,413 postmenopausal women aged 50 to 79
enrolled in the WHI Observational Study. Type (aspirin (ASA) and non-aspirin NSAID) and duration
of use were recorded at enrollment. During an average follow-up of 11 years, 648 incident melanomas
were diagnosed. We used Cox proportional hazards methods and adjusted for skin type, sun expo-
sure history, and medical indications for NSAID use. Women who used ASA had a 23% lower risk
of melanoma (HR: 0.77, 95% CI: 0.63-0.96). Furthermore, increased duration of use (non-use, <1
year, 1-4 years, and ≥5 years) was associated with an 11% lower risk of melanoma for each increase
in category (p=0.007); chronic ASA users (≥5 years) had a 32% lower risk of melanoma relative to
non-users (HR 0.68, 95% CI: 0.50-0.94). In contrast, non-ASA NSAID use was not associated with
melanoma incidence (HR 1.05, 95% CI: 0.82-1.33), with and without adjustment for duration of
use. A limitation of these results is the observational study design and self-reported nature of NSAID
use. In conclusion, postmenopausal women who used ASA, especially those with intake ≥5 years,
had significantly lower risk of melanoma. These findings suggest that ASA may have a chemopre-
ventive effect against the development of melanoma and warrant further investigation of the causal
relationship in an experimental setting.
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Improvement in performance of skin self-examinations after intervention with interactive
computerized education and telecommunication reminders: A randomized controlled study
S Aneja,1 AK Brimhall,2 DR Kast,2 S Aneja,3 D Carlson,2 KD Cooper1,2 and JS Bordeaux1,2 1 Case
Western Reserve University School of Medicine, Cleveland, OH, 2 Department of
Dermatology, University Hospitals Case Medical Center, Cleveland, OH and 3 Yale School of
Medicine, New Haven, CT
Our objective was to determine if interactive computer assisted patient education, self-skin exam-
ination tutorials, and telecommunication reminders could be combined to improve performance of
self-skin examinations, confidence in ability to identify melanoma, and sun protective behaviors.
Two hundred and ten adult participants were enrolled in an interventional study and randomized
to the control or intervention group. The intervention group: (1) participated in a computer assisted
learning tutorial, (2) took part in a hands-on self-skin examination tutorial, (3) received monthly
telecommunication reminders to perform self-skin exams, and (4) received a brochure on melanoma
detection. The control group only received the brochure on melanoma detection. Survey data was
collected from all participants on the day of enrollment and three months after enrollment. Logis-
tic regressions, controlling for race, age, gender, education and family history of melanoma, were
used to assess the effectiveness of the intervention. At the 3-month follow-up, those in the inter-
vention group were 2.36 times more likely to perform self-skin examinations (odds ratio = 2.36,
P≤0.05) and more likely to wear sun protective clothing (odds ratio = 2.4, P≤0.05). Those in the
intervention group were more likely to report being confident in their ability to identify melanoma
during a skin exam (odds ratio = 2.72, P≤0.05). In conclusion, computerized education used in con-
junction with self-skin examination tutorials and telecommunication reminders can increase patient
performance of self-skin examinations, confidence in ability to identify melanoma, and use of sun
protective clothing.
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Evaluation of aging around the eyes by spatial frequency analysis of digital images
A Tada,1 S Inoue Torii2 and K Yamazaki1 1 POLA Chemical Industries, Inc., Yokohama, Japan and
2 Kobe Shoin Women’s University, Kobe, Japan
Many women express concern about signs of aging around the eyes, but few studies have specifi-
cally examined how the impacts of aging around the eyes affect the appearance. The present study
aimed to clarify causes of aging around the eyes using spatial frequency analysis technology. Sub-
jects comprised 140 healthy Japanese women (mean age, 49.0 years; range, 19-82 years). Photo-
graphs of the whole face were taken using a single lens reflex digital camera. Using digital images
of the area around the eyes, spatial frequency analysis was performed. We used linear regression
analysis followed by multiple regression analysis. The dependent variable was the age of the sub-
ject, and the independent variables were the red-green-blue (RGB) and gray power values from
spatial frequency analysis. The multiple correlation coefficient was R=0.927, indicating high pre-
cision. Cluster analysis of the gray power values of spatial frequency analysis was performed to
classify the characteristic frequency as a power value classified into four domains. The image of
each domain was made from the original image using the increase or decrease of power values,
and the characteristics of appearance in each domain were estimated. Domain 1, ranging from 1
to 80 cycles/image-width (c/iw), showed a negative correlation with subject age, and was related
to the size of the eyes, contrast between the sclera and the iris and dark circles. Domain 2 ranged
from 81 to 180 c/iw, showed a positive correlation with subject age, and was related to sagging and
fine wrinkles. Domain 3, ranging from 181 to 300 c/iw, showed a positive correlation with subject
age, and was related to texture and roughness of the skin. Domain 4 showed no relationship with
aging around the eyes. Using power values for each domain, we established a method of estimat-
ing the age of a Japanese woman based on the appearance of the area around the eyes. This study
classified the frequency of characteristics of the area around the eyes into three domains by ana-
lyzing digital images of women’s eyes using spatial frequency analysis.
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HPV is associated with non-melanoma skin cancer in HIV
SI Goolamali,1 N Mladkova,2 KJ Purdie,2 MN de Koning,3 WG Quint,3 N Francis,4 N Morar,1
R Meys,1 CA Harwood2 and CB Bunker1 1 Dermatology, Chelsea and Westminster Hospital,
London, United Kingdom, 2 Dermatology, QMUL, London, United Kingdom, 3 DDL, Rijswijk,
Netherlands and 4 Histopathology, ICSM, London, United Kingdom
In HIV there is a x3-5 risk of non-melanoma skin cancer (NMSC). Human papillomavirus (HPV) is
causal in anogenital cancer and proposed as a co-factor with UV radiation in cutaneous squamous
cell carcinoma (SCC), particularly in transplant recipients. In a case/control study we have studied
HPV in HIV+ve and -ve individuals in actinic keratoses (AKs), SCC-in-situ (CIS), basal cell carci-
noma (BCC) and SCC. DNA was extracted from microdissected, formalin-fixed, paraffin-embedded
tissue and was typed for beta, genital and cutaneous HPV by broad-spectrum, highly sensitive assays.
53 lesions were analyzed from 21 HIV+ve cases (15 BCC, 6 SCC, 3 CIS) and 25 HIV-ve controls (9
BCC, 14 SCC, 1 CIS, 5 AK). In the HIV+ve cases, genital types were most prevalent, followed by
beta and then cutaneous. HIV +ve: genital HPV types detected in 8/12 (66%) of lesions (5 BCC, 2
SCC, 3 CIS: HPV 6, 11, 16, 18, 45,70); beta-types in 6/12 (50%: 4 BCC, 1 SCC, 1 CIS: HPV 8, 9,
14, 20, 25, 36, 75, 92, 96); cutaneous types in 3/12 (25%; 3 BCC: all HPV1). HIV–ve: genital types
detected in 10/16 (63%: 3 BCC, 6 SCC, 2 AK: HPV 6, 16, 18, 52,74); beta types in 5/16 (31%: 3
BCC, 1 SCC, 2 AK: HPV 8, 15, 22, 23, 24, 25, 36, 76, 80, 92, 93, 96); cutaneous types in 6/16
(38%: 2 BCC, 4 SCC: HPV 1, 4, 27). Multiple HPV types were identified in 5/12 (42%) HIV+ve and
5/16 (31%) HIV-ve individuals. In summary, HPV is highly prevalent in NMSC of both HIV+ve and
-ve patients. Although isolated from non-genital skin, genital HPV types, including high-risk onco-
genic types 16 and 18, were the most common in both patient groups. Beta-types, reportedly the
most prevalent HPV type in NMSC, were less common. 35% of HPV+ve tumours contained more
than one HPV type. NMSC in HIV appears to be associated with a different spectrum of HPV com-
pared with immunocompetent individuals.
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Risk of atrial fibrillation among psoriasis patients undergoing cardiac catheterization
S Azizi,1 J Farrow,1 K Klem,1 D Anderson,1 JH Rogers,1 EJ Armstrong1 and AW Armstrong2 1
Cardiology, University of California Davis, Sacramento, CA and 2 Dermatology, University of
California Davis, Sacramento, CA
Psoriasis patients may have an increased risk of developing atrial fibrillation (AF). We sought to
determine whether this increased risk for AF is attributable to established risk factors. All patients
with and without psoriasis who underwent cardiac catheterization from 2005-2010 were identified
using a nested case-control study design. Baseline demographics were obtained and electrocar-
diograms were reviewed for all subjects. The 10-year predicted risk for incident AF was calculated
using the Framingham AF risk score. A total of 169 patients with psoriasis and without AF were age
and gender-matched to control patients without a history psoriasis or AF. Patients with psoriasis had
a higher BMI (31.5 ± 8 vs. 29.2 ± 7, p = 0.008) and higher baseline LDL (100 ± 35 vs. 92 ± 34, p
= 0.04). Other baseline and electrocardiographic characteristics did not differ between patients with
psoriasis and controls. The 10-year estimated risk of incident AF was 12.8% ± 10.7% for patients
with psoriasis and 14.7% ± 10.8 % for patients without psoriasis (p = 0.1). There was no associa-
tion between psoriasis severity or duration and predicted risk of AF. Current risk scores do not pre-
dict an increased risk for AF among patients with psoriasis. The increased incidence of AF among
patients with psoriasis may not be captured in current risk scores.
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Filaggrin mutations: Prognosis and response to therapy overtime
DJ Margolis,1,2 N Mitra,2 A Sandilands,3 I McLean3 and T Rebbeck2 1 Dermatology, University of
Pennsylvania, Philadelphia, PA, 2 Epidemiology, University of Pennsylvania, Philadelphia, PA
and 3 Epithelial Genetics Group, University of Dundee, Dundee, United Kingdom
Loss-of-function mutations in the filaggrin gene (FLG) have been shown to be associated with Atopic
Dermatitis(AD). The goal of this study was to determine if FLG mutations are predictive of the long-
term course of children with AD. DNA obtained from 840 subjects participating in the multiyear
Pediatric Eczema Elective Registry (PEER) study were screened for the four most prevalent FLG muta-
tions (R501X, 2282del4, R2447X, and S3247X) using Taqman-based allelic discrimination assays
(Applied Biosystems). All subjects in PEER can use any therapy to treat their AD and they report on
their AD clinical activity every 6 months. Using an additive model, mutations were then evaluated
individually and as an “any mutation” composite with respect to AD activity. In order to account
for variability in clinical response over time, an analysis was conducted using generalized linear
latent and mixed models (GLLAMM, logit link function). Participants were followed for a mean of
35 months (SD 20.6, median 36 months). Individuals with FLG mutations were less likely [OR:0.54
95% CI:(0.41, 0.69)] to report that their skin was clear of dermatitis. Mutations were less common
in those of African ancestry as compared to European, but the odds ratios were similar (0.54 versus
0.41, respectively). With respect to individual mutations, the estimates were similar with odds
ratios that varied from 0.47 to 0.66. However, skin free of symptoms of AD that did not require con-
comitant therapy (most commonly topical steroids) was least likely to occur in those with the 501X
mutation [0.40(0.21, 0.75)] and was more likely to occur in those with 2282del4 or S3247X (1.71
(0.88, 3.30); 3.34 (1.46,7.66)] mutations. In conclusion, individuals with FLG loss-of-function muta-
tions are less likely to report skin improvement over time and these mutations do not all respond
similarly to therapy.
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Increasing sustainability of teledermatology practices: A study of operational models and chal-
lenges in modern-day teledermatology
AW Armstrong,1 MW Kwong,2 L Ledo,1 TS Nesbitt1 and SL Shewry2 1 Dermatology, University
of California Davis, Sacramento, CA and 2 Center for Connected Health Policy, Sacramento,
CA
Despite increasing practice of teledermatology in the U.S., teledermatology practice models and
real-world challenges are rarely studied. The primary objective was to examine teledermatology
practice models and shared challenges among teledermatologists in California, focusing on prac-
tice operations, reimbursement considerations, barriers to sustainability, and incentives. We sys-
tematically identified all practicing teledermatologists from January 1, 2007 through March 30, 2011
through CMS billing records and AAD and ATA membership lists. We conducted one-hour in-
depth interviews with seventeen teledermatologists from academia, private practice, health main-
tenance organizations, and county settings in California. Among them, 76% practiced store-and-
forward only, 6% practiced live-interactive only, and 18% practiced both modalities. Only 29%
received structured training in teledermatology. The average number of years practicing telederma-
tology was 4.29 years (SD±2.81). Approximately 47% of teledermatologists served at least one Fed-
erally Qualified Health Center. Over 75% of patients seen via teledermatology were at or below
200% federal poverty level and usually lived in rural regions without dermatologist access. Prac-
tice challenges were identified in the following areas. Teledermatologists faced delays in reim-
bursements and non-reimbursement of teledermatology services. The primary reason for operational
inefficiency was poor image quality and/or inadequate history. Costly and inefficient software plat-
forms and lack of communication with referring providers also presented barriers. Teledermatology
enables underserved populations to access specialty care. Improvements in reimbursement mech-
anisms, efficient technology platforms, communication with referring providers, and teledermatol-
ogy training are necessary to support sustainable practices.
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Cardiovascular risk factors and risk for recurrent cardiovascular events among psoriasis patients
undergoing cardiac catheterization
JM Farrow,1 EJ Armstrong,1 K Klem,1 D Anderson,1 S Azizi,1 JC Rutledge,1 JH Rogers1 and
AW Armstrong2 1 Cardiology, University of California Davis, Sacramento, CA and 2
Dermatology, University of California Davis, Sacramento, CA
Psoriasis increases the risk of myocardial infarction, but risk factors among this patient population
have yet to be assessed in the setting of more advanced cardiovascular disease. We established a
database of patients that have undergone cardiac catheterizations from 2005 to 2010 at University
of California Davis. In this cohort, psoriasis patients were age- and gender-matched with patients
that underwent cardiac catheterizations but without a history of psoriasis. Baseline risk factors
were assessed, and the Framingham Heart Study 2-year risk calculator was used to calculate the
risk of recurrent coronary events. A total of 198 psoriasis patients underwent cardiac catheteriza-
tion. Psoriasis patients had significantly higher total cholesterol, LDL, and triglycerides compared
to controls. Patients with psoriasis also had a slightly higher 2-year Framingham risk score for recur-
rent cardiovascular events (8.5 ± 4.2% vs. 8.3 ± 4.0%, p =0.08). The median duration of psoriasis
prior to cardiac catheterization was 8 years. Duration of psoriasis ≥ 8 years was independently
associated with a 33% increase in the Framingham risk score (95% CI 1.20-1.47, p <0.001) even
after adjusting for standard risk factors. Patients with psoriasis and a history of coronary artery dis-
ease may have increased risk of future coronary events compared to age- and gender-matched con-
trols. A longer duration of psoriasis may also positively correlate with an increased Framingham
risk score and subsequently a greater likelihood of recurrent coronary events.
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Cutaneous findings predict the presence of systemic symptoms in pediatric urticaria pig-
mentosa
M Barnes, L Van, L Delong and L Lawley Dermatology, Emory University, Atlanta, GA
Although the prognosis of urticaria pigmentosa (UP) is often benign, clinicians lack the data to reli-
ably predict those at risk for associated systemic manifestations. We sought to elucidate clinical
markers of disease severity in order to provide better treatment and prognostic information for UP
patients. We performed a retrospective chart review querying characteristics of all patients (<15
years old) diagnosed with UP in the Emory Pediatric Dermatology Clinic within the last 25 years.
Follow-up was obtained through a clinical encounter or a phone interview. Linear regression was
used to determine predictors of the number of UP-related systemic symptoms. Of 67 subjects, 43%
were female and the mean(SD) follow up was 5.6 years (range 1-19 years). 20 subjects had follow
up >5 years. The median age of onset was 0.25 years. The maximum number of UP lesions was 1-
10 in 16%, 10-30 in 33%, 31-50 in 25%, 51-100 in 6%, and >100 in 20% of subjects. 78% of sub-
jects reported lesions on the head and neck, 93% on the trunk, 60% on the upper extremities, and
69% on the lower extremities. The number of these body sites involved was 1 in 8%, 2 in 20%, 3
in 29%, and 4 in 43% of subjects. In their UP lesions, 25% of subjects reported blistering, 46%
itching, and 34% flushing. Systemic symptoms reported by subjects were headaches (8%), bone
pain (10%), irritability (6%), diarrhea (22%), vomiting (10%), abdominal pain (15%), wheezing/dys-
pnea (13%), cough (10%), rhinorrhea (8%), anaphylaxis (1.5%). The number of systemic symptoms
reported was 1 in 13%, 2 in 3%, and 3 or more in 20% of subjects. In a multivariate linear regres-
sion analysis, the maximum number of UP lesions and the number of skin symptoms were statisti-
cally significant predictors of the number of systemic symptoms (p=0.02 and p<0.01, respectively)
while controlling for age of onset, body sites involved, and gender. This information could aid cli-
nicians in identifying patients most in need of systemic therapy.
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An online approach to melanoma education aimed at the Hispanic population improves knowl-
edge and behaviors
CJ Roman1 and JS Bordeaux1,2 1 Case Western Reserve University School of Medicine,
Cleveland, OH and 2 Dermatology, University Hospitals Case Medical Center, Cleveland, OH
Our objective was to determine if an online educational program aimed at the Hispanic popula-
tion could change their attitudes, beliefs and behaviors regarding melanoma. Participants were asked
to take a pretest to determine their baseline knowledge of melanoma risk factors, prevention and
self-skin examinations (SSE). Participants then watched a video in Spanish addressing these topics.
Immediately following the video participants completed a questionnaire regarding the content. One
month after viewing the video, participants completed a follow-up questionnaire. One hundred
thirty seven participants completed step 1, 107 participants completed step 2 and 90 participants
completed step 3. The mean age of participants was 39.9 years with a standard deviation 12.7 and
a range of 18-70 years. There was no significant difference between the gender, personal and fam-
ily history of melanoma, and skin type of the participants of each step. The percentage of partici-
pants that knew none of the melanoma risk factors decreased from 35% on step 1 to 4% on step 3
(p <0.0001). The percentage of participants that knew no ways to prevent melanoma decreased from
31% on step 1 to 1% on step 3 (p <0.0001). The percentage of participants that knew nothing to
look for during a SSE decreased from 64% on step 1 to 4% on step 3 (p <0.0001). Ten percent of
participants reported performing a SSE in the last month on step 1, which increased to 79% on step
3 (p <0.0001). On step 3, 77% of participants stated that they had incorporated melanoma pre-
vention into their daily lives. In addition, 7% stated that they shared the information of the video
with family and friends. This suggests that an online approach can be a useful tool in educating and
improving behaviors regarding melanoma prevention and SSE.
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Willingness-to-pay stated preferences in cutaneous lupus erythematosus: A pilot study
SW Liu, C Lam, A Qureshi and R Vleugels Dermatology, Clinical Research Program, Brigham
and Women’s Hospital, Harvard Medical School, Boston, MA
Cutaneous lupus erythematosus (CLE) is a chronic skin condition that has a major impact on health-
related quality of life (QOL). We pilot tested a new method to measure QOL in CLE by eliciting
willingness-to-pay (WTP) stated preferences via the recently developed WTPQoL (willingness-to-
pay quality of life) instrument and a ranking task for 9 domains of health relevant to CLE: intimacy,
physical comfort, self-care, ability to work or volunteer, photosensitivity, ability to concentrate, emo-
tional health, social comfort, and ability to sleep. Ten participants with a history of CLE were inter-
viewed in a face-to-face format. First, participants were asked to rank the 9 domains of health in
the order of degree of impact on their cutaneous lupus-related QOL. Second, participants were
asked how much money they would be willing to pay for a hypothetical cure for each domain.
Responses in US dollars were interpreted as strength of preference rather than absolute monetary
values. All participants (100%) were female, with a mean age of 41.8 years. Forty percent had a
college degree or further education, and 50% had an income level over $35,000/y. Physical com-
fort, photosensitivity, and social comfort were highly ranked by 70% of respondents. Intimacy and
ability to concentrate were least likely to be affected by CLE with 10% of respondents ranking each
of these domains as important. The median amount patients were willing to pay for a hypothetical
cure for CLE specific to a particular domain was highest for photosensitivity ($200,000, 25th quar-
tile = $10,000, 75th quartile = $7,750,000) and lowest for self-care ($0, 25th quartile = $0, 75th
quartile = $875). This study successfully pilot tested a WTP method and a ranking task to measure
the relative severity of 9 domains of health-related QOL and found that physical comfort, social
comfort, and photosensitivity were the domains of health most affected by CLE, while participants
were willing to pay the most for a hypothetical cure for the photosensitivity associated with their
CLE.
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Predictors of squamous cell carcinoma in a high-risk population: VA Topical Tretinoin Chemo-
prevention Trial (VATTC)
AE Rizzo, RK Dyer, T Cohen and MA Weinstock VA Medical Center and Brown University,
Providence, RI
Invasive squamous cell carcinoma (SCC) of the skin is one of the most common cancers in the United
States, with no proven means for prevention other than systemic retinoids, which have significant
toxicity, and sunscreen. We sought to determine risk factors for SCC on the face or ears in a high-
risk population by using data from the VA Topical Tretinoin Chemoprevention (VATTC) Trial. This
cohort included 1131 veterans diagnosed with at least two keratinocyte carcinomas (KCs) in the
previous five years who participated in a randomized trial of high-dose topical tretinoin for KC pre-
vention. The Cox proportional hazards model was used to estimate the adjusted hazard rate ratios
(HRR) and 95% confidence intervals (CI) of each potential predictor of new SCCs on the face and
ears. The median duration of follow-up was 3.7 years; 23% of the participants developed a new
SCC, and the cumulative risk of SCC was 30% at 5 years. The following factors predicted new
SCCs: number of SCCs and number of SCCs in situ in the prior 5 years; actinic keratoses count at
enrollment; and history of ever use of 5-fluorouracil. Total occupational time spent outdoors and
total days outdoors while vacationing in geographical regions below latitude 25 without the use of
sunscreen (>SPF15) were also independent predictors. Finally, a (self-reported) history of warts was
found to have a protective effect against new SCCs (HRR = 0.67, 95% CI 0.52-0.86). Many studies
based on serology have suggested a role for HPV in the carcinogenesis of KCs. However, prior stud-
ies have shown little to no association between a history of warts and SCCs. The number of basal
cell carcinomas in the prior 5 years, sunburns, sun sensitivity, and recreational sun exposure were
not associated with new SCCs. These findings identify key risk factors and suggest a history of warts
may be associated with reduced SCC risk.
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A comparison of the body mass index (BMI) profiles of patients seen in the academic der-
matology and general medicine clinical settings
N Smith, H Chubb and Y Helfrich Department of Dermatology, University of Michigan, Ann
Arbor, MI
Obesity (BMI≥30) has been associated with an increased incidence of neoplastic dermatologic con-
ditions including malignant melanoma. We compared the BMI profiles of patients presenting over
the course of four weeks to a university hospital general dermatology clinic (DC) and general med-
icine clinic (GM). BMI was calculated as kg/m2 using recently measured height and weight values
from the medical record. Self-reported height and weight values from DC patients were used when
measured biometrics were unavailable. Average BMI of GM patients (29.0, N=1323) was signifi-
cantly higher than that of DC patients (27.8, N=851; p<0.001). Average BMI of female (29.1, N=655)
and male (28.9, N=668) GM patients was also significantly higher than that of female (27.5, N=484;
p<0.001) and male (28.1, N=367; p<0.05) DC patients. A significantly higher BMI among GM
patients in the 40-49 (29.7, N=200), 60-69 (30.3, N=251), and 70-79 (28.7, N=169) age groups
was observed, compared to DC patients in the same groups, respectively (27.7, N=122; p<0.05),
(28.4, N=195; p<0.01), and (27.2, N=117; p<0.05). Caucasians were the only racial group to dis-
play a significant difference in BMI between GM (29.0, N=947) and DC (27.7, N=736; p<0.001)
patients. Interestingly, the average BMI of DC patients presenting for skin checks and skin cancer
follow-up visits (27.0, N=448) was not only significantly lower than the BMI of GM patients pre-
senting for new patient and health maintenance visits (27.9, N=316; p<0.05), it was also signifi-
cantly lower than the BMI of DC patients presenting for all other reasons (28.6, N=403; p<0.001).
Heavier patients may be less likely to present for routine skin examination due to body image con-
cerns. In addition, an obese body habitus may contribute to a technically challenging skin exami-
nation and result in decreased self- or PCP-detection of suspicious lesions; the observed disparities
in BMI between DC and GM patients may represent an insufficient screening of the obese popula-
tion for neoplastic dermatologic processes including melanoma.
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Effect of a web-based curriculum on primary care practice: The basic skin cancer triage trial
A Markova, MA Weinstock, P Risica, W Shaikh, U Kirtania and H Ombao Brown University and
VA Med Ctr, Providence, RI
Primary care physicians (PCPs) are uniquely positioned to detect melanoma. Effective educational
interventions targeted at PCPs may improve early melanoma detection. A previous in-person Basic
Skin Cancer Triage (BSCT) 2-hour course demonstrated significant short-term improvement in provider
practices, attitudes, ability, confidence, and knowledge. We conducted a randomized trial to test
the efficacy of the BSCT course implemented as a web-based learning program, compared to a
similar (control) web-based course on weight assessment. We recruited a sample of 57 primary
care physicians (PCPs) and 3341 of their patients from 4 geographically diverse centers. Skin can-
cer control activities by PCPs were assessed by physician survey, and by chart review and patient
telephone interview about their recent visit to their PCP at baseline and at 1-2 months and 12 months
after course completion. Some effect of intervention on skin cancer parameters was self-reported
by physicians, this was not confirmed by patient survey or chart-extracted data. Rates of skin can-
cer control practices by PCPs were low across both groups at pre- and post- intervention. The pos-
itive changes in physician-reported behaviors [total body skin examination (TBSE), p=0.04], inten-
tions [discuss skin cancer detection, p= 0.002], confidence [performing TBSE, p=0.03], office
practices, and knowledge [58% BSCT vs. 49% control, p= 0.0039] were neither matched by dif-
ferences in practice reported by their patients, nor persisted in a longer term follow-up, hence may
be attributable to physician recall bias due to the experience of the course or desire to please study
investigators, and were less dramatic as compared to our previously reported in-person BSCT inter-
vention. Thus this approach by itself appears unlikely to result in improved PCP handling of skin
cancer issues. We are further developing this educational delivery method as a more interactive,
online education curriculum entitled INFORMED (INternet curriculum FOR Melanoma Early Detec-
tion), using improved technology and extensive PCP input.
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Molecular epidemiology of non-syndromic ARCI in a Middle Eastern population
S Israeli,1 D Fuchs-Telem,1 R Bergman,2 M Indelman,2 O Bitterman-Deutsch,3 A Harel,1
Y Mashiach,1 O Sarig1 and E Sprecher1 1 Tel Aviv Medical Center, Tel Aviv, Israel, 2 Rambam
Medical Center, Haifa, Israel and 3 Nahariya Western Galilee Hospital, Nahariya, Israel
Autosomal recessive congenital ichthyoses (ARCI) form a complex and heterogeneous group of dis-
orders of cornification, manifesting with often severely disfiguring generalized scaling of the skin,
and occasionally associated with secondary infections and malignancies. ARCI prevalence rate
and subtype distribution in the Middle East are unknown; however, previous data collected in a
cohort of patients with epidermolysis bullosa, suggest that the demographic features specific to this
region of the world, such as a high frequency of consanguineous marriages, may impact on the
molecular epidemiology of ARCIs as well. We present here the result of systematic screening of all
families successively referred to our centers with a clinico-pathological diagnosis of ARCI. All patients
were initially genotyped with an updated panel of 23 microsatellite markers, spanning all known
ARCI genes. Mutation analysis was then performed initially in genes located in regions displaying
homozygosity. In case no mutations were found in these regions, all other ARCI genes were fully
scrutinized for pathogenic mutations. A total of 20 families with non-syndromic ARCI were ana-
lyzed. Pathogenic mutations were found in all ARCI genes including TGM1 (30%), ALOX12B (20%),
ALOXE3 (10%), ABCA12 (5%), CYP4F22 (10%), LIPN (5%) and NIPAL4 (5%). Out of 20 families,
two (10%) were found to map to the 12p11.2–q13 locus while one other did not exhibit mutation
in any of the known ARCI genes. Out of 20 families, 12 are of Arab Moslem origin. In this sub-
group, mutations were most often identified in ALOX12B (34%) while the non-Arab Moslem part
of our cohort displayed a subtype distribution very similar to that previously reported in Western
populations. These data point to the need for population-tailored mutation screening strategies in
inherited diseases characterized by genetic heterogeneity, which take into account the relative preva-
lence of disease subtypes.
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DNA repair is critical in maintaining neurologic integrity and hearing function: A 40 yr lon-
gitudinal auditory analysis of patients with xeroderma pigmentosum and trichothiodystro-
phy 
MB Totonchy,1,2 D Tamura,1 C Zalewski,3 PT Bradford,4 JJ DiGiovanna,1 KH Kraemer1 and
CC Brewer3 1 Derm Branch, NCI, Bethesda, MD, 2 CRTP fellow, NIH, Bethesda, MD, 3
Otolaryngology Br, NIDCD, Bethesda, MD and 4 Genetic Epi Br, NCI, Bethesda, MD
We assessed the role of DNA repair in the maintenance of normal hearing and neurologic integrity
by examining hearing loss and neurologic function in patients with xeroderma pigmentosum (XP)
and trichothiodystrophy (TTD), rare autosomal recessive disorders of DNA repair and premature
aging. In addition to photosensitivity and skin cancer, progressive XP-type neurodegeneration (XPND)
develops in a subset of XP patients. Prediction of patients who will develop XPND is clinically dif-
ficult. TTD features include brittle hair, photosensitivity, ichthyosis, intellectual impairment, and
developmental delay. We performed a retrospective follow-up study using audiograms and clinical
data of 100 patients (77 XP and 23 TTD) examined at the NIH from 1971-2011. A total of 216 audio-
grams were analyzed. XPND was present in 17 XP patients and 7 patients had non-XPND. Of the
XPND patients, 15/17 underwent pure tone testing, 80% (n=12) of whom developed clinically sig-
nificant hearing loss (4 frequency pure tone average (4FPTA) >20dB) by age 24, while the other 3
were under age 16. All 17 XP patients who developed XPND were XP-A or XP-D and reported acute
burning on minimal sun exposure (ABOMSE) while 19% (10 of 53) had ABOMSE without neuro-
logic disease. In XP patients with ABOMSE between the ages of 4-30, the 4FPTA≥7.5dB was asso-
ciated with an 18- fold increased odds (p=0.04) of developing XPND. The 19 yr mean age of clin-
ically significant hearing loss in the XP patients with XPND was approximately 57 yrs younger than
in the general population. Many XP patients without XPND had subclinical hearing loss. Of 23
TTD patients, 39% (n=9) had clinically significant hearing loss. We show that audiometric analy-
sis, ABOMSE and age are important predictors of XPND. These results indicate that DNA repair is
critical in maintaining neurologic integrity of the auditory system.
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High throughput screening for transcriptional inducers of IGFBP7 points to histone deacety-
lases as new therapeutic targets in psoriasis
N Sagiv,1 J Nousbeck,1 V Shoshan-Barmatz,2 D Fuchs-Telem,1 O Sarig1 and E Sprecher1 1 Tel Aviv
Medical Center, Tel Aviv, Israel and 2 Ben-Gurion University, Beer Sheva, Israel
We recently identified IGFBP7 as a key regulator of keratinocyte proliferation, differentiation and
apoptotic activity. Moreover, IGFBP7 was found to be down-regulated in psoriasis, while recombi-
nant IGFBP7 was found to cure psoriasis in a humanized mouse model. In the present study, we
aimed at identifying transcriptional inducers of IGFBP7 as potential new therapeutic agents in pso-
riasis. To achieve this aim, we generated HeLa cell lines constitutively expressing a luciferase reporter
gene under the regulation of various parts of the putative IGFBP7 promoter. After having selected
the most responsive construct using IFN-gamma as a positive control, we screened a total of 1496
compounds derived from the NCI Diversity SetIII and oncology drugs set III chemical libraries.
Vorinostat, a histone deacetylase inhibitor, was found to reproducibly induce IGFBP7 promoter
activity as well as to up-regulate endogenous IGFBP7 expression in HeLa cells by more than 2 fold
in a time- and dose-dependent manner. To ascertain the physiological relevance of our findings, we
compared global gene expression in cells treated with vorinostat vs. vehicle using theHumanHT-
12 v4 Expression BeadChip Kit (Illumina). A large number of genes known to be associated with
psoriasis pathogenesis were found to be affected by vorinostat (e.g. IFNA, KLK11, CCL2). In addi-
tion, ingenuity pathway analysis revealed that among the biological networks most significantly
associated with vorinostat treatment were the IGF1- (p value = 0.0036) and IL-17 (p value = 0.0058)
signaling pathways, of direct relevance to psoriasis. Finally, in a preliminary set of experiments, we
demonstrated that systemic (i.p.) administration of vorinostat to mice treated with imiquimod to
induce a psoriasis-like dermatitis, resulted in a significant decrease in epidermal hyperplasia. The
present data suggest that histone deacetylase inhibitors may be of potential use in the treatment of
psoriasis and other hyperproliferative skin disorders.
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Topical immunomodulation with diphenylcyclopropenone for alopecia areata: The Lebanese
experience
J El Khoury,1 J Abd-El-Baki,1 F Succariah1 and M Kurban1,2 1 Dermatology, American University
of Beirut, Lebanon, Lebanon and 2 Biochemistry and Molecular genetics, American University
of Beirut, Beirut, Lebanon
Alopecia Areata (AA) is an autoimmune disease that primarily affects the hair follicle and results in
patchy hair loss. The response of AA to therapy is highly variable. Topical immunotherapy with
Diphenylcyclopropenone (DPCP) is a treatment that can be used in AA patients with more that
50% involvement of the scalp. The aim of this study is to assess the response of our patients with
AA treated with topical immunotherapy with DPCP at the American University of Beirut-Medical
Center and to characterize the favorable prognostic factors that predict response to treatment. This
is a retrospective study of patients diagnosed with AA at AUB-MC and treated with DPCP over a
period of 10 years. Data was collected for analysis including the type of AA that was defined as lim-
ited, totalis or universalis. The grade of hair regrowth was defined on physical exam as follows:
Grade 0 = no hair, Grade1 = vellus hair only, Grade 2 = Sparse pigmented hair, Grade 3 = Termi-
nal hair growth with patched of alopecia, Grade 4 = Terminal hair growth over whole area. The
response to treatment was defined as an increase in the grade on Physical exam and a relapse was
defined as a decrease in the grade. A total of 34 cases were included for analysis.The majority of
patients had limited AA (58.8%) with a mean of 39% of scalp involvement. The remaining patients
had alopecia universalis (29.4%) and alopecia totalis (11.8%). The percentage of patients that
responded to DPCP therapy was 79.3%. Of the patients who responded, 10 relapsed (29.4%) and
the mean time to relapse was 74.6 weeks from the initiation of treatment. A negative family history
of atopy was found to be protective against relapse (p= 0.02). The most common side effect of ther-
apy was itching (82 %) followed by contact dermatitis (51.7%), blistering (17.2 %) and cervical lym-
phadenopathy (13.8 %).
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Differences between invasive and in situ melanoma according to age of diagnosis, mortality,
host risk factors and lifetime ambient UV exposure
AC Walls,1 J Han,1,2 T Li2 and AA Qureshi1,2 1 Dermatology, Brigham and Women’s Hospital,
Boston, MA and 2 Channing Laboratory, Harvard Medical School, Boston, MA
Incidence of malignant melanoma in-situ (MMIS) is rising in the US but there is little data on MMIS
risk. We evaluated the differences between MMIS and MM based on age of diagnosis, mortality rate,
host risk factors and UV index. Prospective data from 250,151 women and men over 20+ years in
the Nurses’ Health Study (NHS), NHS2 and Health Professionals Follow-up Study (HPFS) was col-
lected and analyzed. Incident MMIS, MM and melanoma-related deaths were confirmed via pri-
mary review of pathology report and death certificates. Participants were stratified according to
host phenotypic risk factors and UV index of their state of residence at birth, age 15yrs and age
30yrs. We calculated multivariate relative risks using Cox proportional hazard models. 2,682
melanoma lesions occurred during 7,144,820 person-years of follow-up. MMIS represented
33%(n=888)of melanoma cases. Significant difference in age of diagnosis was seen in women but
not men (NHS MMIS=64.8yrs, MM=59.4yrs, P<0.0001; NHS2 MMIS=47.0yrs, MM=44.9yrs,
P<0.0001; HPFS MMIS=67.4yrs, MM=65.9yrs,P<0.10). Mortality rates for MMIS were lower in
women as compared to men (NHS MMIS=8.7 deaths/yr/1000 individuals, MM=22.8; NHS2,
MMIS=0.79, MM=5.1; HPFS MMIS=22.4, MM=49.3, P<0.0001). Lifetime residence in a state with
a medium UV index was associated with increased risk of MMIS among older women but not among
younger women or men (NHS RR 1.45 [95%CI 1.08-1.95]; NHS2 0.82 [0.57-1.18]; HPFS 0.67
[0.42-1.06]). The presence of 1-2 nevi on an extremity was associated with significantly increased
risk of MMIS but not MM; fewer number of sunburns conferred significantly increased risk of MM
as compared to MMIS; other differences were seen related to family history, hair color and sunburn
susceptibility. This study showed MMIS is significantly different from MM in age of diagnosis, mor-
tality rate, association with UV index of state of lifetime residence and phenotypic characteristics
and helps define risk factors unique to MMIS.
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Variation in dermatologist beliefs about the safety and effectiveness of treatments for mod-
erate-to-severe psoriasis
K Abuabara,1 J Wan,1 AB Troxel,2,3 DB Shin,1,3 AS Van Voorhees,1 BF Bebo,4 GG Krueger,5 K Callis
Duffin5 and JM Gelfand1,2,3 1 Department of Dermatology, University of Pennsylvania,
Philadelphia, PA, 2 Center for Clinical Epidemiology and Biostatistics, University of
Pennsylvania, Philadelphia, PA, 3 Department of Biostatistics and Epidemiology, University of
Pennsylvania, Philadelphia, PA, 4 National Psoriasis Foundation, Portland, OR and 5
Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT
We aimed to describe dermatologist’s perceptions of the safety and effectiveness of psoriasis treat-
ments and evaluate how these relate to dermatologist characteristics and treatment preferences. A
random sample of 500 National Psoriasis Foundation (NPF) members and 500 American Academy
of Dermatology (AAD) members who treat psoriasis received a mail survey (39% response rate).
Beliefs about the safety and effectiveness of treatments for moderate-to-severe psoriasis were assessed
by the following questions: “What percent of patients treated with each of the following therapies
will have clear or almost clear skin after three months?” and “What percent of patients will have to
discontinue each of the following therapies due to side effects (i.e., lab abnormalities, adverse effects
or general tolerability issues)?” Respondents perceived infliximab, ustekinumab, cyclosporine, and
adalimumab to have the highest likelihood of skin clearance in three months (67-75%). Etanercept,
adalimumab, UVB, and ustekinumab had the lowest perceived likelihood of side effects requiring
treatment discontinuation (9-11%). Up to 49% of respondents “didn’t know” the effectiveness or
likelihood of side effects; calculated coefficients of variation were higher for perceived likelihood
of side effects than perceived effectiveness. There were few significant associations between safety
and effectiveness perceptions and respondent characteristics, and treatment preferences were only
weakly predictive of perceptions. Psoriasis providers demonstrate wide variation in their percep-
tion of the effectiveness and especially safety of systemic treatments.
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Association of eyeglasses use with periocular keratinocyte carcinomas and actinic keratosis
KC Lee1,2 and MA Weinstock1,2,3 1 Dermatology, Brown University, Providence, RI, 2
Dermatoepidemiology, VA Medical Center, Providence, RI and 3 Cooperative Studies
Program, U S Department of Veterans Affairs, Washington D.C, DC
Eyeglasses may reduce the flux of ultraviolet light to periocular skin, although data to support their
effect on reduction of skin cancer risk is lacking. Using data from the prospective Veterans Affairs
Topical Tretinoin Chemoprevention Trial, we examined the role of eyeglasses use on periocular
keratinocyte carcinoma and actinic keratoses (AK) risk. Subjects were examined every 6 months for
development of new skin cancers or AKs, and interviewed regarding risk factors and eyeglasses
use. Of 1131 participants recruited from 6 centers, 1031 (91%) responded to questions about eye-
glasses use below age 40 and 956 (85%) above age 40. At baseline, number of previous periocu-
lar basal cell carcinomas (BCCs) was not associated with eyeglasses use (OR 1.4, 95% CI 0.9-2.0
for use under age 40, and OR 1.3, 95% CI 1.3-2.0 for use after age 40). In contrast, number of pre-
vious periocular squamous cell caricinomas (SCCs) was associated (OR 3.3, 95% CI 0.9-11.6 for
use before age 40 and OR 3.9, 95% CI 1.3-12.0 for use after age 40). At 72 months, 71 periocular
BCCs, 19 periocular SCCs, 12 periocular squamous cell carcinoma in situ (SCCis), and 3291 peri-
ocular AK were diagnosed. After adjusting for known predictors of BCCs, number of previous BCCs
(p=.01) and older age (p=.044) were significant for development of new BCCs on univariate analy-
sis. On multivariate analysis, only number of previous BCCs (p=.043) was significant. Due to low
numbers of periocular SCC and SCCis diagnosed, no variables, including glasses use, were associ-
ated. In contrast, various known predictors of SCC development were associated with periocular
AKs on multivariate analysis: number of previous SCCs (p=.02), number of AKs at study initiation
(p<.001), ever use of 5-fluorouracil (p=.03), history of warts (p=.03), older age (p=.03), and eye-
glasses use (p=.04). These findings suggest an effect of eyeglasses in reducing the risk of periocular
AKs, but not BCCs.
www.jidonline.org   S43
SID12_Abstracts-2  2/21/12  8:10 AM  Page S43
ABSTRACTS | Epidemiology & Health Services Research
257
Desired improvement tool (DIT): A new tool to assess desire for additional treatment and
minimal disease activity in psoriasis patients 
D Zaghi,1 J Ying,3 C Weir,2 K Callis Duffin1 and G Krueger1 1 Dermatology, University of Utah,
Salt Lake City, UT, 2 Biomedical Informatics, University of Utah, Salt Lake City, UT and 3
Internal Medicine, University of Utah, Salt Lake City, UT
Our objective was to 1) Describe the psychometric properties of a new patient-reported outcome
tool, the Desired Improvement Tool (DIT). 2) Use the DIT to characterize patient-defined minimal
disease activity (MDA) in psoriasis. DIT is a 0-5 scaled tool. A 0 indicates patient is satisfied with
disease level and does not desire further treatment. A 5 indicates a large amount of further treat-
ment desired. Our design was a cross-sectional, correlational measurement study. Six outcomes
were collected from 268 moderate-to-severe psoriasis patients over 911 visits. Two were patient-
reported outcomes, DIT and Life Quality Assessment (LQA). The LQA is a 0-100 quality of life tool.
The remaining four were investigator-reported outcomes: Psoriasis Area and Severity Index (PASI),
body surface area (BSA), Physician Global Assessment (PGA), and the product of BSA and PGA
[BSAxPGA]. Predictive validity, construct validity and responsiveness to change were determined.
Descriptive statistics and receiver operating curves (ROC) were used to characterize minimal dis-
ease activity (MDA), defined as disease level in patients who desired no further treatment (DIT=0).
Our results showed that the DIT demonstrated moderately high predictive and construct validity
(Spearman Rho correlations: BSA 0.7, PGA 0.56, PASI 0.67, PGAxBSA 0.71, LQA 0.67; P-values <
0.001). A sensitivity analysis revealed the DIT is responsive to changes in BSA. Mean values of
patients at MDA (DIT=0) were: BSA 0.57, PGA 0.82, PASI 0.87, PGAxBSA 1.00, LQA 5.46. Fitness
of BSA to predict MDA was good (area under ROC curve: 0.87). BSA ≤ 0.5 predicted MDA with
79% specificity and 79% sensitivity. In conclusion, DIT demonstrates validity and responsiveness
to change in psoriasis. Using the DIT, we characterize patient-defined MDA. The DIT may be a more
informative and understandable patient-reported outcome tool in psoriasis clinical trials and patient
care.
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Low-fat dietary pattern and skin cancer risk: The Women’s Health Initiative (WHI) random-
ized controlled dietary modification trial
CA Gamba,1 ML Stefanick,1 JM Shikany,2 J Larson,3 E Linos,1,4 ST Sims,1 J Marshall,5 L Van Horn,6
N Zeitouni5 and JY Tang1 1 Stanford University School of Medicine, Stanford, CA, 2 Division of
Preventive Medicine, University of Alabama Birmingham School of Medicine, Birmingham,
AL, 3 WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle,
WA, 4 University of California San Francisco School of Medicine, San Francisco, CA, 5 Roswell
Park Cancer Institute and University of Buffalo, Buffalo, NY and 6 Department of Preventive
Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
We evaluated the effect of a low-fat dietary pattern on skin cancer risk among 48,835 postmenopausal
women who consumed a baseline percent fat intake ≥32%, in post-hoc analyses of the WHI ran-
domized trial of dietary modification. Intervention goals included decreasing fat intake (percent fat
intake ≤20%), increasing vegetable and fruit intake (≥5 servings/day), and increasing grain intake
(≥6 servings/day). The intervention group maintained long-term differences in percent fat intake (a
difference of -8.1% versus the comparison group at year 6) and increased vegetable and fruit
intake. During a mean follow-up of 8 years, there were 4,907 incident non-melanoma skin cancers
(NMSCs) and 279 incident melanomas. NMSCs and melanomas were ascertained by self-report
every 6 months. Incident cases of melanoma were confirmed by physician review of medical records.
Rates of incident skin cancer were similar between the randomization groups (NMSC: HR 0.98,
95% CI 0.92-1.04; melanoma: HR 1.04, 95% CI 0.82-1.32). In subgroup analysis, we found that a
low-fat dietary pattern reduced melanoma risk in women who consumed a moderate fat intake at
baseline (e.g., baseline percent fat intake of 32 to 36.8%) (p=0.006). Our results suggest that a low-
fat dietary pattern did not reduce the overall incidence of either NMSC or melanoma, however we
saw a trend for melanoma risk reduction in women consuming moderate fat levels at baseline. Fur-
ther investigations of larger dietary change or the effect of lower baseline fat intake on skin cancer
risk are warranted.
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Predictors of pediatric eczema severity in the United States: A population-based study
JI Silverberg1 and EL Simpson2 1 Dermatology, St. Luke’s-Roosevelt Hospital Center, New York,
NY and 2 Dermatology, Oregon Health & Science University, Portland, OR
The distribution and determinants of atopic dermatitis (AD) severity are not well established. We
used the 2007 National Survey of Children’s Health to determine the prevalence estimates and risk
factors for AD stratified by disease severity, from a nationally representative sample of 91,642 chil-
dren age 0-17 years. Nationwide, 13.0% (95% CI: 12.4 – 13.5) of children were reported to have
a diagnosis of AD in the past 12 months; 67.0% (95% CI: 64.8 – 69.2) reportedly had mild, 26.0%
(95% CI: 23.9 – 28.1) moderate and 7.0% (95% CI: 5.8 – 8.3) severe disease. The prevalence of
severe eczema ranged from 2.0 to 12.9% between states and districts, with the highest prevalence
of severe disease reported in South Carolina, Michigan, Arkansas and Pennsylvania and the lowest
prevalence in Alaska, Georgia, Missouri and Arizona. Factors associated with more severe eczema
in univariate models include increasing age (Rao-Scott chi-square, P = 0.0002), Black race (P <
0.0001), family structure with a single mother/no father present (P < 0.0001), lower level of pater-
nal and maternal education (P = 0.002 and < 0.0001, respectively), decreasing household income
(P < 0.0001), and factors associated with poverty such as dilapidated housing (P = 0.0009) and
garbage on the street (P = 0.001). In multivariate models including age, race/ethnicity and sex, all
of the abovementioned covariates remained significant except for paternal education (multinomial
logistic regression, P < 0.01). These data suggest that socioeconomic factors influence AD disease
severity. In addition, older children tend to have more severe disease.
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Eczema severity is associated with multiple comorbid conditions and increased healthcare
utilization
JI Silverberg1 and EL Simpson2 1 Dermatology, St. Luke’s-Roosevelt Hospital Center, New York,
NY and 2 Dermatology, Oregon Health and Science University, Portland, OR
Atopic dermatitis (AD) is associated with multiple comorbid conditions, such as allergic asthma and
food allergy. The impact of eczema severity on the development of these comorbid disorders is not
well established. We previously reported a direct relationship between skin disease severity and
the presence of mental health conditions in AD. In the current study, we used the 2007 National
Survey of Children’s Health, a nationally representative sample of 91,642 children age 0-17 years,
to determine the prevalence of various comorbid disorders in AD stratified by disease severity. In
general, more severe eczema correlated with a decreased report of overall health (P < 0.0001),
impaired sleep (P = 0.003) and increased healthcare utilization, including seeing a specialist (P <
0.0001), compared to children with mild disease. Severe eczema was associated with a higher preva-
lence of comorbid chronic health disorders (Rao-Scott chi square, P < 0.0001), including asthma
(P = 0.002), hay fever (P < 0.0001), and food allergies (P < 0.0001). In addition, the severity of
eczema was directly related to the severity of the comorbidities. Severe eczema was also associ-
ated with recent dental problems, including toothache (P = 0.02), bleeding gums (P = 0.0007), and
tooth decay (P = 0.02). These data indicate that severe eczema is associated with multiple comor-
bid chronic health disorders, impaired overall health and increased healthcare utilization. Further,
these data suggest that children with eczema are at risk for decreased oral health. Future studies are
warranted to verify this association.
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Relative humidity, dew point, indoor heating and ultraviolet index are associated with the
prevalence of eczema
JI Silverberg,2 JM Hanifin1 and EL Simpson1 1 Dermatology, Oregon Health & Science
University, Portland, OR and 2 Dermatology, St. Luke’s-Roosevelt Hospital Center, New York,
NY
Eczema is often associated with xerosis and exacerbation during winter months. However, the role
of specific environmental exposures, such as humidity, temperature and ultraviolet (UV) radiation,
on the US prevalence of eczema and other atopic disorders is unknown. We hypothesized that
geographical regions with higher humidity and increased UV radiation may have a lower preva-
lence of atopic dermatitis due to the protective effects of skin hydration and photoactive factors.
We used a merged analysis of the 2007 National Survey of Children’s Health from a nationally rep-
resentative sample of 91,642 children age 0 – 17 years and the 2006 – 2007 National Climate Data
Center and National Weather Service measurements of relative humidity (%), dew point (degrees
celcius), indoor heating degree days (base of 65 degrees Fahrenheit), clear sky UV index, issued UV
index (inclusion of cloud effects), ozone levels (parts per billion), and air temperature (degrees
Fahrenheit). In multivariate models controlling for sex, race/ethnicity, age and household income,
eczema prevalence was significantly lower with higher relative humidity (logistic regression, P ≤
0.008), particularly humidity ≥ 40%, and higher dew point, especially in the months of November
through April (P ≤ 0.003). Eczema prevalence was also significantly lower with higher clear sky and
issued UV indexes (P = 0.0003 and 0.0001), particularly with high to extreme values (index ≥ 6; P
≤ 0.0005), decreased ozone levels (P = 0.0002), and higher air temperature. In contrast, eczema
prevalence was significantly higher with increased heating degree days in all months except June
(P ≤ 0.008). In contrast, neither severity of eczema nor comorbid atopic disorders were associated
with any of the above mentioned environmental variables. These data suggest that increased humid-
ity, temperature and UV exposure are protective against childhood eczema, but they may not impact
other atopic disorders.
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Do we know the cost of dermatologic specialty care? A survey of dermatology providers, res-
idents and patients
JA Mann,1 VM Carlberg,1 AB Kimball,2 FJ Storrs,1 A Blauvelt1 and EL Simpson1 1 Dermatology,
Oregon Health & Science University, Portland, OR and 2 Dermatology, Massachusetts
General Hospital, Boston, MA
Numerous studies demonstrate a lack of awareness of the cost of medications and procedures among
primary care physicians in the US. No study has evaluated this issue within the field of dermatol-
ogy. We surveyed dermatology providers, residents, and patients to ascertain their understanding
of, and opinions regarding, dermatologic care costs. A survey was administered to 221 dermatol-
ogy patients; 50.7% were university-based and 49.3% were from randomly selected practices in
Portland. A second survey was given to 54 dermatology providers within the state of Oregon, and
a third survey was completed by 48 dermatology residents and fellows from 4 west coast universi-
ties. Response rate was above 75% for all three surveys. 78.5% of patients stated that it was impor-
tant to them to receive an estimate of the out-of-pocket cost of a dermatologic medication, how-
ever only 34.3% of patients reported that medication cost was discussed during their appointment.
Over one quarter (26.2%) of patients opted not to fill a prescription at the pharmacy because it was
too expensive, and 21.1% of patients reported using an expensive medication less often than pre-
scribed to make it last longer. Confirming this finding, 72.9% of dermatology residents stated that
it was common for prescriptions they had written to go unfilled because of cost. 72.9% of residents
also reported having been asked by patients to discuss the cost of a medication or procedure because
their attending had not done so. Of the providers surveyed, nearly half (45.3%) reported that they
only mention the cost of a medication if they suspect the patient will have to pay for it entirely out
of pocket. On average, dermatology providers underestimated the true cost of 4 common trade name
medications by 40.7%. Improving dermatologists’ knowledge of the cost of medications and pro-
cedures and integrating discussion of these issues into office visits could improve patient satisfac-
tion and adherence to medication regimens.
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The availability of free samples of acne medications increases the prescription of more expen-
sive, branded drugs in lieu of generic alternatives
M Hurley, R Stafford and A Lane Stanford University School of Medicine, Stanford, CA
Despite an increase in the use of free medication samples by Dermatologists over the past decade,
the effect of these samples on prescription preferences has not been evaluated. The prescriptions
written in 2010 for patients with a primary, new diagnosis of acne (ICD-9: 706.1, 695.3) were com-
pared between two local clinics, one allowing and one not allowing samples. For medications that
were prescribed at least three times for acne (comprising 87% and 90% of all such prescriptions at
each site), branded drugs accounted for 61.3% and 27.3%, and generics accounted for 38.7% and
72.7% of the prescriptions written at the clinic that did and did not allow samples, respectively
(p<0.001). Ten of the 15 different sampled acne medications were within the 20 most prescribed
medications for the clinic allowing samples, but none of these drugs were frequently prescribed at
the site without samples. Regression analysis, adjusting for multiple patient characteristics and
clustering by provider, shows a strong association between Dermatologists who practiced with sam-
ples and the prescription of a branded drug (OR: 9.69; 95% CI: 7.09, 13.25), indicating that the
selection of branded medication is likely unrelated to disease severity. The average retail cost of each
prescription for the Dermatologists who practiced with samples was $141.33 higher ($203.25 vs.
$61.92). Nationally representative data from the IMS Health National Disease and Therapeutic
Index™ was also used to assess the generalizability of our findings. Of the medications prescribed
by office-based Dermatologists in 2010 for patients presenting with acne for the first time, 79% were
branded or branded generic and 21% were generic. Furthermore, 12 out of the top 15 most used
samples were also within the 15 most prescribed medications to all patients in 2010 as reported by
Dermatologists in the same database. Dermatologists should be aware of the costs of prescribed
medications and how the use of free samples may influence prescription behavior and increase
health care expenses.
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Internet crowdsourcing as a venue for collection of dermatologic quality of life data
A Ostrowski,1 S Chen,2,3 E Veledar,2 A Sperduto2 and R Swerlick2,3 1 Medical College of Georgia,
Augusta, GA, 2 Emory University School of Medicine, Atlanta, GA and 3 Atlanta Veterans
Administration Medical Center, Atlanta, GA
Crowdsourcing is defined as “the act of sourcing tasks traditionally performed by specific individ-
uals to a group of people or community (crowd) through an open call.” It has been widely deployed
in the business community to solve problems and accelerate information exchange across large
populations at lower costs. Health-care themed websites, such as CureTogether, exploited this idea
to become sources of medical information for lay-populations. We sought to determine the feasi-
bility of using crowdsourcing for dermatology research. Information was collected using conven-
tional one on one survey methods from 160 subjects at The Emory Clinic and from 211 anonymous
subjects visiting the CureTogether website. Subjects in each arm of the study completed a demo-
graphic survey, as well as Skindex and ItchyQoL. Responses were analyzed for completion timeli-
ness, completeness, reliability reproducibility, and overall quality-of-life scores. Conventional meth-
ods required less time to collect the target 160 surveys (70 vs. 296 days). However, the crowdsourced
approach showed the fastest rate of collection (36 vs. 90 surveys) during the best seven-day period.
CureTogether subjects were younger, more educated, less likely to speak primarily English, sub-
scribed more to online social networking sites, had a higher percentage of Caucasians, and less
likely to require systemic medications for treatment of their skin condition. Both groups had simi-
lar levels of missing data (6% vs. 8%) for baseline Skindex and also showed high internal reliabil-
ity and reproducibility with >0.8 Cronbach α and intraclass correlation coefficients for both Skindex
and ItchyQoL. Both groups had similar Skindex/ItchyQOL scores in the Acne (p=0.1/0.32) and
Eczema/Atopic Dermatitis (p=0.09/0.31) subgroups. This study demonstrates proof of principle for
the potential use of the crowdsourcing method for collecting dermatology patient-reported data.
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Obesity and melanoma risk: The Skin Health Study
RL Ahmed, RI Vogel and D Lazovich Dermatology, Masonic Cancer Center, and Epidemiology
and Community Health, University of Minnesota, Minneapolis, MN
Studies have suggested positive associations between obesity and melanoma. The majority of these
included few cases and/or did not adjust for confounding factors for melanoma. We used a popu-
lation-based case-control study to evaluate associations between obesity and melanoma. The Skin
Health Study had 1167 cases of invasive melanoma identified through the state cancer registry, and
diagnosed in MN from 2004-2007 at ages 25-59. 1101 age- and gender-matched controls were
selected from state driver’s license lists. Self-administered questionnaires and telephone interviews
queried height and weight, as well as established melanoma risk factors, including phenotype,
indoor tanning and outdoor sun exposure. Age- and multivariate-adjusted odds ratios and 95% con-
fidence intervals (OR[95%CI]) were calculated. We explored whether or not melanoma risk factors
varied by body mass index (BMI, <25, 25-29.9, >30 kg/m2). In cases and controls combined, phe-
notype did not vary by BMI. Indoor tanning use was higher in women with low vs. high BMI, and
low in men. Women’s sun exposure (routine, activity, occupation) did not vary by BMI, whereas
sun exposure increased with higher BMI in men. Given the variation, these factors were accounted
for in the analyses. In age-adjusted analyses, positive associations with elevated levels of anthro-
pometric characteristics (continuous) and melanoma in men (467 cases, 441 controls) were iden-
tified for: height (Pval=0.01), weight (Pval=0.04), and body surface area (BSA) (Pval=0.01), but not
BMI (Pval=0.3). With multivariate adjustment, these associations were attenuated and no longer sig-
nificant. Among women (688 cases, 653 controls), increasing levels of weight, BMI and BSA were
associated with decreased melanoma in multivariate-adjusted analyses: Pval = 0.01, 0.01, and 0.04,
respectively. Similar findings were seen for trend across categories of these variables. After adjust-
ment for traditional melanoma risk factors, we observed inverse associations between markers of
obesity and melanoma in women, but not in men.
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Characterization of SEER-reported unknown melanoma thickness cases
W Shaikh,1 S Dusza,1 A Geller,2 A Halpern1 and M Weinstock3 1 Mem Sloan Kettering, NY, NY,
2 Harvard Med & Pub Hlth School, Boston, MA and 3 VA Med Ctr, Providence, RI
Effective melanoma prevention and control efforts are dependent on accurate cancer surveillance.
In the US, the Surveillance, Epidemiology, and End Results (SEER) Program is the authoritative source
for population-based data on melanoma. Despite SEER’s commitment to quality improvement and
control, a significant proportion of cases are missing data on tumor thickness, the key prognostic
factor. Hence we sought to characterize unknown thickness cases. We analyzed non-occult micro-
scopically-confirmed invasive melanomas in the SEER-17 registries from 1989 to 2008. Of 182205
cases, 24348 (13.36%) had unknown thickness. Over time the proportion of unknown thickness
cases has been steadily decreasing; from 22.75% during 1989-1993 to 9.13% during 2004-2008.
A multivariate logistic regression model revealed that unknown thickness cases compared to known
thickness cases are significantly more likely to be fatal, very young (0-14) or elderly (65+), minori-
ties or unknown race, not married or unknown marital status, not superficial spreading or nodular
subtype, on the head/neck or site not-otherwise-specified, and in counties with a higher proportion
of residents with less than a high school education, a lower proportion of residents with a white
collar job, or a lower proportion of residents below the poverty level. Odds of dying from melanoma
were significantly higher among unknown thickness cases compared to known thickness cases (OR
3.48, 95% CI 3.35-3.61) with an increasing trend over time. Categorization of known thickness
cases into 0.01-1.00, 1.01-2.00, 2.01-4.00, or > 4.01 mm groups demonstrated similar odds of dying
from melanoma among the 2.01-4.00 mm (OR 9.61, 95% CI 9.08-10.17) and unknown thickness
group (OR 9.55, 95% CI 9.09-10.04). Although SEER has made great strides in reducing the pro-
portion of unknown thickness cases, our study highlights an important limitation in using the SEER
database: exclusion of unknown thickness cases, which tend to have poorer prognoses, may be con-
tributing to an underestimation of thick and fatal melanomas.
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Progression from cutaneous to systemic lupus erythematosus by ACR criteria usually occurs
with mild disease and few systemic symptoms
IT Wieczorek,1,2 KJ Propert,3 J Okawa1,2 and VP Werth1,2 1 Department of Dermatology,
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, 2 Department of Dermatology,
University of Pennsylvania, Philadelphia, PA and 3 Center for Clinical Epidemiology and
Biostatistics, University of Pennsylvania, Philadelphia, PA
We characterized the types and severity of systemic symptoms in a cohort of patients with cuta-
neous lupus erythematosus (CLE). 196 patients with CLE who presented between January 2007 and
April 2011 to a university autoimmune skin disease clinic were included in this prospective, lon-
gitudinal cohort study. At the first visit, 111 (56.6%) patients had CLE only, and 85 (43.4)% had sys-
temic lupus erythematosus (SLE) in addition to CLE. Prior to or at the first visit, patients with both
CLE and SLE had musculoskeletal (69.4%), renal (36.5%), hematologic (30.6%), cardiopulmonary
(12.9%), and neurologic (10.6%) involvement; 86.6% of these patients went on to have no or mild
additional systemic symptoms during the study. Of 85 patients with CLE who had more than 1 visit,
13 (15.3%) went on to meet SLE criteria, with a mean (95% CI) time from CLE diagnosis to SLE of
8.0 ± 3.4 years; 61.5% of these converters developed none or mild additional systemic symptoms
during the follow up period. When compared to studies of general SLE patients, our patients with
CLE and SLE have fewer systemic manifestations at baseline, and most developed none or mild addi-
tional systemic disease. A greater percentage of patients with CLE who converted to SLE during the
study developed moderate to severe systemic symptoms when compared to patients with long-
standing SLE, suggesting a need for continued monitoring of CLE patients.
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Natural product use in sunscreens and their annual economic burden
B Ma,1 R Johal,1 T Ma,1 RR Isseroff,1,2 HI Maibach3 and RK Sivamani1 1 Dermatology, UC Davis,
Sacramento, CA, 2 Dermatology, Veterans Affairs, Mather, CA and 3 Dermatology, UC San
Francisco, San Francisco, CA
Naturally derived products are commonly added in over-the-counter products, including sunscreens.
Here we aimed to understand the prevalence of natural product extracts among sunscreens avail-
able at retail stores and estimate annual economic burden. Overall, 62% of sunscreens include a
natural product extract and 79% include a vitamin derivative. Name brand sunscreens used more
natural product extracts per sunscreen (1.66 ± 0.22) than store brands (1.00 ± 0.22, p < 0.05).
However the number of vitamins per sunscreen was similar between name brand (1.96 ± 0.11) and
store brand sunscreens (1.69 ± 0.15, p = 0.15). The three most commonly used natural products
extracts were derived from aloe vera (29.3%), licorice root (17.8%), and soybean (6.3%). The three
most common vitamins used in sunscreens were derivatives of vitamin A (58.6 %), vitamin C (40.8
%), and vitamin E (40.3 %). Name brand sunscreens rated at an SPF of 30, 50, and 70 were signif-
icantly more expensive in comparison to store brand sunscreens of a similar SPF. However, name
brand and store brands were similarly expensive when compared at an SPF rating of 100. The annual
economic burden for an adult male using SPF 50 sunscreen daily to the arms, face, upper chest,
upper back, and the legs (for half the year) was estimated to be $402.61 and $196.36 for a name
brand or a store brand sunscreen applied at 2 mg/cm2, respectively. When accounting for actual
application density (1 mg/cm2) rather than ideal application density (2 mg/cm2), this economic bur-
den was reduced to $201.30 and $98.18 for the use of name brand or store brand sunscreens, respec-
tively. Our findings show that natural product extracts and vitamins are prevalent with more natu-
ral product extracts in name brand sunscreens. In addition, the financial burden for using sunscreen
regularly under actual use conditions is not economically unfeasible. Although natural product use
is prevalent in sunscreens, their effects remain largely unknown and will require further investiga-
tion.
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The relationship between emotional stress and beliefs about facial skin aging
JM Schultz Product and Consumer Research Center, Avon Products, Inc., Suffern, NY
A considerable body of research in the biological and social sciences has demonstrated how stress
can negatively impact health. Further, the symptoms of stress often manifest in ways that mirror the
effects of premature aging. While there does appear to be broad public awareness of emotional
stress as a health concern, it is not clear that consumers understand what specific effects stress can
have on their skin, or if this understanding results in increased purchase or use of anti-aging skin-
care products. To investigate this question, an internet-based survey was conducted with 697 con-
sumers from the US, Brazil, and China. Participants were administered the Perceived Stress Ques-
tionnaire along with a battery of other measures, including questions regarding their lay theories
and self-perceptions of aging. Results showed that an overwhelming majority of those sampled
believed that stress did cause premature aging of their facial skin. Further, those who scored above
the median on Perceived Stress were significantly more likely to believe that many specific mani-
festations of aging were caused by stress. High Perceived Stress individuals were also more likely
to report personal incidence of a number of specific aging-related facial skin imperfections, and
more likely to report use of a number of skincare products. These findings suggest that opportuni-
ties do exist for the development and marketing of facial skin care products that specifically target
consumers who perceive themselves to be highly stressed.
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Prevalence of comorbidities is lower among HLA-Cw6-positive psoriasis patients
T Tejasvi,1,2 PE Stuart,1 RP Nair,1 JJ Voorhees1 and JT Elder1,2 1 Dermatology, University of
Michigan, Ann Arbor, MI and 2 Dermatology, Veteran Affairs Medical Center, Ann Arbor, MI
It is becoming increasingly evident that the impact of psoriasis on the health of the patient goes far
beyond skin or joint inflammation to include obesity, metabolic syndrome and cardiovascular dis-
ease. Thus, metabolic syndrome was 2.9-fold more frequent among German psoriatics relative to
controls, with similar findings emerging from NHANES data in the US. Despite these reports, stud-
ies examining a possible genetic basis for the comorbidities of psoriasis are few. We evaluated self-
reported questionnaires of 200 psoriasis patients and 393 healthy controls (age at evaluation < 40
years) for occurrence of myocardial infarction, hypertension, hyperlipidemia and diabetes mellitus,
and determined the presence or absence of HLA-Cw6 by SNP typing. Hypertension was more preva-
lent in psoriasis patients than controls (26/171 vs. 25/366, OR=2.23, p=0.0079), as was hyperlipi-
demia (43/149 vs. 36/343, OR=2.75, p<0.0001). Among the psoriasis cases, both comorbidities
were less prevalent in carriers of the HLA-Cw6 allele (6/80 vs. 20/91, OR=0.34, p=0.0325 for hyper-
tension and 9/72 vs. 34/77, OR=0.28, p=0.0015 for hyperlipidemia). Both of these comorbidities
were also of lower prevalence in HLA-Cw6 carriers when the sample was expanded to include
psoriatics of any age (n=1138 cases), although the association was weaker (184/274 vs. 318/362,
OR=0.76, p=0.0326 for hypertension; 192/249 vs. 337/332, OR=0.75, p = 0.027 for hyperlipi-
demia). There was no association between HLA-Cw6 carriage and these comorbidities in unaffected
controls regardless of their age. This study suggests that HLA-Cw6 may protect against development
of comorbidities of psoriasis; alternatively other genetic loci may increase risk for hypertension and
hyperlipidemia in HLA-Cw6-negative psoriasis patients.
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The impact of patient and physician gender on awareness of visit’s goals
A Rogers,1 LK DeLong,1,2 SC Chen,1,2 RA Swerlick1,2 and K Neyman3 1 Emory University, Atlanta,
GA, 2 Atlanta VAMC, Atlanta, GA and 3 Department of Medicine, Section of Dermatology,
University of Chicago Medical Center, Chicago, IL
Gender differences between patients and their physicians may impact how patients interact with
their physicians as well as physician communication style. Our investigation aimed to assess the
impact of patient and physician gender on physicians’ awareness of patients’ goals of a particular
encounter. Patient and physician participants completed a post-encounter questionnaire assessing
their perception of the patient’s concerns and goals. The primary outcome was level of concor-
dance between patient and physician responses, and analysis was performed according to patient-
physician gender pairings. Differences between gender concordant (male-male and female-female)
and discordant (male-female and female-male) patient and physician pairings were determined using
a chi-square test for two questions: (1) chief complaint (e.g. growth vs. rash) and (2) current vs. future
problem (i.e., seeking reassurance).There were a total of 148 patient-physician pairs. The physician
correctly identified the chief complaint in 91% of the 90 gender concordant dyads vs. 81% in the
58 gender discordant pairs (p=0.07). There was no statistically significant difference between patient-
physician gender pairs in terms of identifying current vs. potential future problem. These data sug-
gest that there may be a trend towards impaired communication in gender discrepant patient-
physician pairings. Additional physician training may be warranted to better tailor physician
communication to patient needs and facilitate improved physician-patient communication.
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Pre-diagnostic plasma 25-hydroxyvitamin D and risk of non-melanoma skin cancer in women
G Liang,2 H Nan,2 AA Qureshi1,2 and J Han1,2 1 Dermatology, Harvard Medical School, Boston,
MA and 2 Channing Laboratory, Harvard Medical School, Boston, MA
Recent reports have shown that vitamin D status was inversely associated with the risk of various
cancers. However, few studies examined the association between vitamin D levels and risk of skin
cancer. We prospectively evaluated the association between baseline plasma 25(OH)D levels and
the risk of incident squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) among 4,641
women from the Nurses’ Health Study (NHS) and the NHS II with 510 incident BCC cases and 75
incident SCC cases. We used multivariate logistic regression models to calculate odds ratio (OR)
and 95% confidence interval (CI). Plasma 25(OH)D levels were positively associated with risk of
BCC after adjusting for age at blood draw, season of blood draw, lab batch, hair color, burning ten-
dency, the number of sunburns, and ultra-violet B flux of residence at blood collection. Women in
the highest quartile of 25(OH)D had more than 2-fold increased risk of BCC compared with women
in the lowest quartile (OR=2.07, 95% CI=1.52-2.80, P for trend <0.0001). We also found a signif-
icantly positive association between plasma 25(OH)D levels and SCC risk after adjusting for the
same covariates (OR, highest vs. lowest quartile =3.77, 95% CI=1.70-8.36, P for trend =0.0002).
The stratified analysis suggested that the association between plasma 25(OH)D levels and BCC risk
was stronger among women whose blood was not collected during the summer, who lived in areas
with less ultra-violet B flux, and those who were lightly pigmented (P for interaction=0.09, 0.07,
and 0.15, respectively). In this prospective study of women, plasma vitamin D levels were posi-
tively associated with non-melanoma skin cancer risk. This suggests that one-time measurement of
plasma vitamin D levels may reasonably reflect long-term sun exposure and predict the risk of non-
melanoma skin cancer.
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Atopic dermatitis prevalence and co-morbidities in US women
L Lin,1,3,4 J Han,1,2,3 C Camargo2,3 and AA Qureshi1,3 1 Department of Dermatology, Brigham
and Women’s Hospital, Boston, MA, 2 Department of Epidemiology, Harvard School of Public
Health, Boston, MA, 3 Channing Laboratory, Department of Medicine, Brigham and Women’s
Hospital, Boston, MA and 4 School of Public Health, Guangxi Medical University, Nanning,
China
Atopic dermatitis (AD) is a chronically relapsing inflammatory skin disorder with high prevalence
reported in industrialized countries. We evaluated the prevalence of AD and co-morbidities in the
Nurses’ Health Study II (NHS II) and their children in the Growing Up Today Study I (GUTS I). Women
responding to the same question on atopic disorders in the GUTS I maternal questionnaire in 2006
and the NHS II main questionnaire in 2009 were included in this study. We used logistic regression
analyses to estimate effects of environmental risk factors, family history of atopy and association
with other allergy disorders. A total of 3,843 women (age range 47-50, mean 49 ± 0.33) had com-
plete responses to both questionnaires. Of these, 568 (15%) reported physician-diagnosed eczema,
532 (14%) food allergies, 2,029 (53%) hay fever and 821 (21%) reported asthma in both question-
naires. Hay fever (RR 0.85, 95% CI 0.71-1.03) and asthma (RR 1.09, 95% CI 0.881-1.355) were not
significantly associated with risk of AD whereas food allergy was significantly associated with risk
of AD (RR 1.57, 95% CI 1.24-1.98). Interestingly, children of women with AD had a significantly
higher risk of AD (RR 2.92, 95% CI 2.15-3.96). In multivariate analyses, we found that smoking (RR
1.03, 95% CI 0.91-1.15), alcohol consumption (RR 0.97, 95% CI 0.88-1.05) and BMI (RR 0.96,
95% CI 0.88-1.04) were also not significantly associated with risk of AD. In this study, we found
that food allergy was associated with risk of AD while asthma and hay fever did not show signifi-
cant associations. Children had a higher risk of developing AD if their mother had AD. There was
no significant evidence suggesting smoking, alcohol consumption and obesity were AD risk fac-
tors.
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Increasing incidence of invasive squamous cell carcinoma in US women and men
K Nguyen,1 J Han,1,2 T Li2 and A Qureshi1,2 1 Department of Dermatology, Brigham and
Women’s Hospital, Boston, MA and 2 Channing Laboratory, Department of Medicine,
Brigham and Women’s Hospital, Boston, MA
The purpose of this study was to examine trends in the incidence of invasive squamous cell carci-
noma (SCC) and associated risk factors in US women and men in the Nurses’ Health Study (NHS)
and Health Professionals Follow-up Study (HPFS). Incident cases of clinician-diagnosed invasive
SCC were obtained biennially since cohort enrollment and confirmed from pathology records. We
examined associations between invasive SCC and known risk factors. Among women, there was a
42.4-fold increase in the age-adjusted incidence rate from 1.91 per 100K person years (1976-1978)
to 81.00 per 100K person years (2006-2008). Among men, there was a 1.6-fold increase in the age-
adjusted incidence rate from 85.35 per 100K person years (1986-1988) to 138.36 per 100K person
years (2006-2008). Body site distribution was different between women and men, with 40% of inva-
sive lesions occurring in the head and neck among women (57% among men) and 19% of lesions
occurring in the lower extremities among women (5% among men). In multivariate analyses, an
increased risk of invasive SCC was associated with a history of painful or blistering sunburns (NHS:
RR 1.41 [95% CI 1.21-1.64]; HPFS: RR 2.16 [95% CI 1.80-2.60]) and 6 or more sunburns in child-
hood (NHS: RR 1.68 [95% CI 1.39-2.02]; HPFS: RR 1.26 [95% CI 1.03-1.54]). Among women but
not men, an increased risk of invasive SCC was associated with a family history of melanoma (RR
1.29 [95% CI = 1.06-1.57]), 6 or more moles on an extremity (RR 1.42 [95% CI 1.12-1.79]), red
hair (RR 1.43 [95% CI 1.14-1.80]), and blonde hair (RR 1.22 [95% CI 1.04-1.44]). The increasing
incidence rate of invasive SCC and differences in body site distribution for women and men may
be attributable to sun exposure habits. This trend warrants further investigation and, possibly, inter-
vention. The confirmation of childhood sunburn susceptibility and the number of childhood sun-
burns as risk factors is useful for identifying individuals who may benefit from closer monitoring for
invasive SCC.
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Web-based curriculum improves primary care providers’ skin cancer detection skills 
MJ Eide,1 M Asgari,2 W Shaikh,3 LL Li,4 SW Fletcher,4 A Halpern,5 A Geller,4 G Alexander,1
A Altschuler,2 S Dusza,5 A Marghoob,5 E Quigley5 and MA Weinstock3 1 Henry Ford Hospital,
Detroit, MI, 2 Kaiser Perm, Oakland, CA, 3 VA Med Ctr/Brown, Providence, RI, 4 Harvard
Medical & Public Health School, Boston, MA and 5 Mem Sloan Kettering, NY, NY
Skin cancer screening requires primary care providers’ (PCP) participation. However, few PCP-ori-
ented curricula are available, and none have evaluated actual changes in practice. We developed
a web-based curriculum to train practicing PCPs in skin cancer detection and evaluated changes
in skills, confidence, and practice behaviors. 54 PCPs were recruited from two HMOs in June
2011. Participants reviewed a 2-hour skin cancer curriculum which included 450 clinical images
and frequent feedback. Pre and post assessments of diagnostic and management skills and attitudes
were completed. Participants’ mean age was 51 years (range 30-69); 54% were female, 33% white,
and 80% internists. Overall diagnostic accuracy improved from 42% to 52% (p<0.01) and correct
referral decisions from 73% to 78% (p<0.01). Improvement in differentiating between malignant
and benign lesions and correct management correlated with pre-test scores; participants who scored
in the lowest quartile on the pretest improved most on the post-test while those who scored in the
pre-test top quartile improved least. Participants with no reported medical school skin cancer train-
ing improved most in the post-test (OR 2; 95% CI 1,3). Confidence in skills also improved (p<0.01).
A web-based interactive curriculum improved PCPs’ short term diagnostic accuracy, confidence,
and management of skin cancer. Greater improvement was seen among lower-scoring PCPs who
were least skilled before the course and those who had not received medical training in skin can-
cer detection.
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The prevalence of stump dermatoses remains high 40 years after amputation
NB Yang,1,2 LA Garza,1 S Kang,1 CE Foote3 and JH Meyerle4,1 1 Dermatology, Johns Hopkins,
Baltimore, MD, 2 Duke-NUS Graduate Medical School, Singapore, Singapore, 3 Indiana
University, Indianapolis, IN and 4 Uniformed Services University of the Health Sciences,
Bethesda, MD
Stump skin disease is a major factor that limits prosthetic use in amputees. We conducted a cross-
sectional study of Vietnam War Veterans 40 years post combat-related amputation. Phone, online,
and paper versions of a validated questionnaire were issued to 453 subjects in the research registry
database of the Indiana-Ohio Center for Traumatic Amputation Rehabilitation Research. The response
rate was 58%. Eight out of 159 questionnaire items assessed dermatological and prosthesis-related
issues associated with amputation occurring in the past 12 months. Of the 247 veterans who suf-
fered major amputations, the average individual was 62 years old, Caucasian (92%), and 40 years
post amputation. Types of amputation were unilateral below the knee (n=84, 34%), unilateral above
knee (n=70, 28%), and bilateral lower extremity limb-loss (n=55, 22%). 119 subjects (48%) reported
skin breakdown or rash within the past year; 39 (16%) experienced the condition for more than six
months, and 40 (16%) required re-adjustment of the prosthesis. In 79 subjects (32%), prosthesis
could not be used for 28 days on average and in 51 individuals (21%) prosthesis had to be altered
or replaced because of stump skin conditions. Pain and discomfort at the stump site affecting the
respondent’s quality of life were reported by 150 veterans (61%). Skin conditions represent one of
the most significant morbidities associated with long term use of prosthesis and contribute to pros-
thesis abandonment. Even 40 years after amputation, we found high prevalence of stump dermatoses.
This suggests the lack of natural adaptation mechanism of stump skin to the prosthesis. The preva-
lence of dermatoses at the stump underscores the importance of skin disease prevention, early man-
agement, and advanced treatment methods in order to facilitate the use of the prosthesis.
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A comprehensive systematic review and meta-analysis of treatments for lichen planus
P Davari, F Gorouhi, H Hsiao and N Fazel Dermatology, University of California, Davis,
Sacramento, CA
Lichen planus (LP) is a relatively common disorder with no definitive cure that affects the skin,
mucous membranes, nails, hair, and rarely esophagus. We performed a systematic review of all
systematic reviews and randomized controlled trials (RCTs) on LP. All forms of LP were considered
in this study. PubMed, EMBASE, all databases in the Cochrane library, Google Scholar, and China
National Knowledge Infrastructure (CNKI) were searched using explicit search strategies. There were
no language restrictions in this study. We identified 9 relevant systematic reviews and 62 RCTs.
Meta-analysis was applied where indicated. Cutaneous LP: Eight RCTs were found for the treat-
ment of cutaneous LP. The following drugs were included: Oral prednisolone, topical hydrocorti-
sone, acitretin, sulfasalazine, griseofuvin, hydroxychloroquine and vitamin D analogues (KH1060
and calcipotriol). Mucosal LP: A total of 54 RCTs (53 on oral LP, 1 on vulvar LP) met the criteria for
mucosal LP. The treatment modalities included topical and systemic corticosteroids, topical cal-
cineurin inhibitors, topical and systemic retinoids, antifungals, psoralen plus ultraviolet A (PUVA),
topical thalidomide, Polysaccharide nucleic acid fraction of bacillus Calmette-Guerin (BCG-PSN),
curcuminoids, purslane, mesalazine, ultrasound, low-level laser therapy, aloe vera, amytriptiline,
Ignatia, vitamin A, mucoadhesive polymers, and hyaluronic acid. High quality evidence is widely
lacking for the main therapeutic choices of cutaneous LP. The meta-analysis was not possible for
this subtype. Although topical corticosteroids are considered as the mainstay of mucosal LP ther-
apy, only two of them (betamethasone valerate and flucinolone) have been proven to be more ben-
eficial than placebo by performing meta-analyses. For many treatment options, there was only one
supporting trial and for many other drugs the evidence is weak. One of the main problems in many
included RCTs was the lack of a clear and accurate measurement of disease outcome or severity.
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Racial disparities in the degree of dyspigmentation and scarring in patients with cutaneous
lupus
SM Verma,1,2 J Okawa,1,2 VP Werth1,2 and K Propert3 1 Dermatology, Univ. of Pennslyvania,
Philadelphia, PA, 2 Dermatology, PVAMC, Philadelphia, PA and 3 Biostatistics, Univ. of
Pennslyvania, Philadelphia, PA
In SLE, racial and ethnic disparities have been reported in disease activity and outcomes, but sim-
ilar information is not available in CLE. Our goal was to determine if CLE patients of different races
exhibit disparities in disease damage and quality of life (QoL). Patients were enrolled into our prospec-
tive database and evaluated with validated scoring tools. Data collected included gender, race, diag-
nosis, Cutaneous Lupus Area Activity and Severity Index (CLASI) scores, and Skindex-29 QoL scores.
These parameters were analyzed from the initial visit and, for patients who came to our clinic more
than once, from the final visit as well. CLASI damage scores (dyspigmentation and scarring) and
CLASI activity scores were collected, grouped by race, and correlated with Skindex-29 scales. 223
patients were analyzed at baseline, with 141 of these patients completing more than one study
visit. The majority of patients were Caucasians (63.7%), followed by African Americans (29.1%) and
Asian Americans (4.0%). African American patients accounted for a disproportionate percentage of
both localized (50% of cases) and generalized (48.9% of cases) DLE. Median CLASI damage scores
significantly differed amongst our Caucasian, African American, and Asian American patients, at
both first (1.0, 9.5, 6.0) (Kruskal-Wallis p<0.0001) and last visit (4.0, 10.0, 8.5) (Kruskal Wallis
p=0.0007),(Dunn’s Multiple Comparison p<0.05). Surprisingly, there was no significant correlation
between CLASI damage scores and Skindex subscores for emotion or function. In contrast, Skindex-
29 symptom scores correlated with both CLASI activity and CLASI damage scores in African Amer-
icans with CLE (Spearman’s r=0.3612, p=0.0058). In conclusion, African American patients with
CLE exhibit a high rate of DLE, as well as dyspigmentation and scarring, at their initial visit but
there was limited correlation between these measures of cutaneous damage and Quality of life meas-
ures of emotion or function.
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Implementing a system to collect outcome measures for psoriasis
PL Mattei, KR Donahue, KC Corey and AB Kimball Dermatology, Massachusetts General
Hospital, Boston, MA
With increasing trends towards outcomes based practice, the demographics and severity of psori-
asis patients presenting to tertiary care centers will be an important consideration for healthcare
resource allocation. The physician global assessment (PGA) seems a good candidate scoring sys-
tem for outcomes because it is intuitive, simple and correlates well with other scores like the PASI.
We systematically collected encounter forms that recorded a PGA score and basic demographic
information from patient visits at MGH Dermatology over a 6 month period from June to Decem-
ber 2011. Patient billing sheets were modified to include a subheading under the psoriasis diagno-
sis section into PGA categories of “Clear,” “Almost Clear,” “Mild,” “Moderate,” and “Severe.” 744
billing sheets were completed for psoriasis patients between June and December 2011. The earli-
est visit for each patient was selected to yield 582 unique patients. Of these patients, 52.4% were
male and 47.6% were female. The mean age of patients was 50.6 years old. When categorized by
severity, 4.3% of patients were “Clear,” 14.1% of patients were “Almost Clear,” 47.9% of patients
were “Mild,” 27.8% of patients were “Moderate,” and 5.8% of patients were “Severe.” Data was
available for a single visit in a 6 month time frame and the seasonal changes of psoriasis may not
be fully appreciated. The demographics of these patients were consistent with previously reported
findings in terms of age and gender. In contrast to previously reported severity incidence, however,
where approximately 16% of patients were classified as moderate to severe, the patients seen at
our tertiary care center, as expected, appeared more likely to suffer from moderate to severe psori-
asis. Future areas of study may examine the change in severity following a year of treatment at a
tertiary care center.
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Visualizing the human dermatologic phenome: Implications for diagnostic error, medical edu-
cation, and scientific inquiry with the other “omics”
L Rimoin,1 A Cruz,2 VM Blanco,2 NG Saravia,2 A Papier3 and N Craft4,1 1 UCLA School of
Medicine, Los Angeles, CA, 2 CIDEIM, Cali, Colombia, 3 University of Rochester, Rochester,
NY and 4 LABioMed at Harbor-UCLA, Torrance, CA
Recent advances in medical informatics, high throughput genetic sequencing technologies, and raw
computing power have led to a variety of new approaches to the study of human disease. Exam-
ples include genomics, transcriptomics, and microbiomics. Digital images and computing tech-
nologies have also allowed us to capture the clinical manifestations of disease more easily and accu-
rately. We have created a novel computing infrastructure and knowledge management system to
house an image collection representing the human disease phenome of signs and symptoms. From
nearly 2 million original images screened to date, we selected over 90,000 images and entered them
with metadata into our database. Our work in visual medicine, diagnostic error, and diagnostic deci-
sion support highlights axes of variation in the human visible disease phenome. This variation can
affect scientific inquiry, the diagnostic process, and medical education. The symptoms associated
with disease states can be represented as continuous variables rather than simple dichotomous
descriptions of health and disease. The ability of the physician-scientist to describe the range of clin-
ical diseases and the associated symptoms will be critical in this effort to help scientists determine
the underlying mechanisms of disease, to help educators build better tools for students, and to help
informaticists build better diagnostic tools for clinicians to use at the point of care. The human dis-
ease phenome database could be mined with high throughput techniques, for perceptual and
adaptive learning research, content-based image retrieval research, or vision science research. In
collaboration with efforts like the Human Variome Project and Human Microbiome Project, it could
also facilitate the discovery of trends, patterns, and previously unappreciated disease characteris-
tics that wouldn’t be possible with anecdotal analysis.
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Internet survey of tattoo skin care
JT Jones,1,2 EK Sandsmark,1 M Salazar,1 BJ Walkosz3 and RP Dellavalle1,2,4 1 Dermatology,
University of Colorado School of Medicine, Aurora, CO, 2 Epidemiology, Colorado School of
Public Health, Aurora, CO, 3 Klein Buendel, Inc., Golden, CO and 4 Dermatology Service,
Denver Veterans Affairs Medical Center, Denver, CO
Cultures around the world have employed the art of tattooing for centuries. While this historic tra-
dition continues to gain popularity, as witnessed by the prevalence of tattoos reaching approximately
25% in the USA, little is known about online tattoo care recommendations. To evaluate these rec-
ommendations we performed an Internet search using the key words “tattoo care” in the search
engine Google® on 1/4/12. The 50 highest ranked results returned links to 48 websites and 2 videos.
Tattoo parlors posted 24 of the websites and the 2 videos. Of the remaining websites, 15 were gen-
eral information websites and 9 were commercial product promotions. The most common short
term post-tattoo recommendations were avoidance of scratching or picking the tattoo (30/50), appli-
cation of anti-bacterial ointment (25/50), ultraviolet (UV) protection (25/50), tattoo washing instruc-
tions (21/50), and avoidance of swimming pools (21/50). Long term UV protection advice was also
commonly provided (19/50), but primarily focused on protecting tattooed skin. Online recom-
mendations for tattoo care vary greatly. More uniform instructions might better prevent adverse out-
comes such as infection or provide better protection from tattoo fading through better sun safety.
Additionally, online tattoo care advice provides a unique educational opportunity to encourage
short and long term sun protection.
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Gender is an age-specific effect modifier for ulcerated malignant melanomas
BS Richardson,1 WF Anderson,3 JS Barnholtz-Sloan,2 MA Tucker4 and MR Gerstenblith1 1
Dermatology, Case Western Reserve University School of Medicine, Cleveland, OH, 2 Case
Comprehensive Cancer Center, Case Western Reserve University School of Medicine,
Cleveland, OH, 3 Biostatistics Branch, NCI, NIH, Bethesda, MD and 4 Human Genetics
Program, NCI, NIH, Bethesda, MD
Gender, age at diagnosis, and ulceration are independent prognostic factors for melanoma. The pur-
pose of this study was to further examine the interactions among these three variables. Using the
NCI’s SEER 17 Registries Database (2004-2008), we assessed ulceration status among white men
and women with malignant melanoma, stratified by younger (ages 10-39 years) and older (ages 40-
84 years) ages at diagnosis as well as by tumor depth. The analysis was restricted to melanomas
common among younger and older persons, i.e. superficial spreading, nodular, and unclassified
melanomas. There were 2905 older men, 301 younger men, 1624 older women and 276 younger
women. Relative risks were expressed as incidence rate ratios (IRR) with 95% confidence intervals
(CI). At every tumor depth, IRRs for ulcerated melanomas were significantly higher for older than
younger persons (IRR>1.0). The trend, however, varied in men and women. In men, the IRR (older
to younger) rose continuously with increasing depth [≤1.0mm: IRR 7.81 (CI 6.18-9.98), 1.01mm-
≤2.0mm: IRR 9.71 (CI 7.55-12.68), 2.01mm-≤4.0mm: IRR 11.04 (CI 8.78-14.06); and ≥4.01mm:
IRR 12.26 (CI 9.60-15.87)]. On the other hand, in women, IRR (older to younger) was stable for all
depths ≤4.0mm then nearly doubled for melanomas ≥4.01mm [≥4.01mm: IRR 8.00 (CI 5.85-11.20)].
As noted by others, our study shows that older age at diagnosis is associated with higher incidence
rates of ulcerated malignant melanomas. Nonetheless, this large-scale population-based analysis
demonstrates an effect modification by gender and tumor thickness, suggesting different biologic
behavior of melanoma in younger and older men and women. Future studies should further inves-
tigate tumor biology differences in these populations and the interaction among gender, age at
diagnosis, and ulceration in melanoma.
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1-year mortality rate in bullous pemphigoid - significant correlation with autoantibody lev-
els against BP180 at time of diagnosis
B Monshi, B Piringer, M Schmidt and K Rappersberger Dermatology, Krankenanstalt
Rudolfstiftung, Vienna, Austria
Mortality rate in patients with bullous pemphigoid (BP) has been investigated in multiple studies
with differing results. In this retrospective study we investigated the possible correlation of various
epidemiological, clinical and immunopathological characteristics with the 1-year and overall mor-
tality rate in a cohort of 41 patients with BP. We collected data of 41 patients diagnosed with BP at
our department between October 2001 and June 2009. Clinical severity at the time of diagnosis
was assessed through evaluation (ABSIS) of clinical photographs (n=26). Missing immunopatho-
logical data (ELISA, indirect immunofluorescence and/or split skin studies) were completed through
analyzing stored serum samples. All patients have been followed up for at least one year. 1-year
mortality was 17.5%; this is a 2.5-fold higher probability of death compared with an age- and gen-
der-matched control group. Levels of autoantibodies against BP180 at the time of diagnosis corre-
lated significantly a) with disease activity (n=26, p=0.03) and b) with the 1-year mortality (n=37,
p=0,008). Moreover, 1-year mortality correlated significantly with the initial dosage of systemic
steroids (n=41, p=0,034). The number of comorbidities only correlated with the mortality over the
whole observational period of 25 months on the average (n=41, p=0,027). Our data show a signif-
icant correlation of autoantibody levels against BP180 at the time of diagnosis with the 1 year mor-
tality rate, implying that disease-specific factors contribute to a higher mortality rate in patients
with BP compared to a gender and age matched control group. Therefore, antibody levels meas-
ured by ELISA could provide a prognostic factor. Initial steroid dosage should also be considered
as a potential risk factor for the increased 1-year mortality. Correlation of the number of comor-
bidities with the overall mortality underscores the importance of close collaborations with other
specialties in the management of BP patients.
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An analysis of terminology used by primary care physicians to describe concerning lesions
referred to an urgent dermatology clinic
K Corey,2,1 M Kardos,3,1 E Roh1 and A Kimball1 1 Dermatology, Massachusetts General
Hospital, Boston, MA, 2 University of Massachusetts, Worcester, MA and 3 Tufts University
School of Medicine, Boston, MA
In response to long wait times in our dermatology clinic, an urgent care clinic was established to
provide patients developing potentially malignant lesions identified by their primary care physician
with timely access to dermatologic care. There was concern that referrals would include mostly
benign conditions and flood the resource. Analysis of the terminology used by referring providers
provides a promising method to triage patients. To determine the proportion of referrals diagnosed
as melanoma, squamous cell carcinoma or basal cell carcinoma and the positive predictive value
of terms used to describe concerning lesions based on final pathologic diagnoses. A retrospective
chart review of 500 urgent referrals to the Department of Dermatology at Massachusetts General
Hospital was completed. This included the first 250 urgent referrals from September 2008-January
2009 and 250 referrals from July 2010. Data were collected including referring diagnoses, descrip-
tive terms, and final clinical and pathologic diagnoses. Out of 500 referrals, 396 were evaluated in
the urgent clinic, and 36 patients (9%) were diagnosed with malignancy. Of these, 8% (n=3) were
melanoma, 44% (n=16) were SCC, and 47% (n=17) were BCC. Common terms used to describe
concerning lesions included suspicious for BCC (n=19), pigmented (n=16), raised (n=16), non-
healing (n=14), suspicious for SCC (n=11), irregular (n=7), and bleeding (n=6). These descriptions
predicted cancer 0-14% of the time except for suspicious for BCC and suspicious for SCC, which
demonstrated positive predictive values of 42% and 27% respectively. Personal or family history of
skin cancer was listed as a concern for 17 patients, of which 1 was diagnosed with SCC. Discus-
sion: The majority of referrals were non-malignant. Descriptors, particularly “nonhealing” and
“suspicious for BCC” or “suspicious for SCC,” may provide clues to help dermatologists triage patients.
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Race and eosinophilia in mycosis fungoides: Retrospective study of eosinophilia and race
J Zampella and GA Hinds Johns Hopkins, Baltimore, MD
Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma (CTCL). It is associated
with eosinophilia which portends a poorer prognosis. MF is more common in African Americans
(AA) and follows a more aggressive course compared to whites. We further elucidate the relation-
ship of blood or tissue eosinophilia and race in patients with MF. The records of 564 patients with
MF were reviewed for demographic, clinical and laboratory data. We found 345 patients with MF
(62% white, 31% black and 7% other). Average age at diagnosis was 45 for AAs and 55 for whites
(p<0.001). Average median blood eosinophils demonstrated eosinophilia in all patients (AAs 476
cells/ml, whites 451 cells/ml (p=0.2)). Of patients with blood eosinophilia, the average maximum
blood eosinophil count was 2,039 in AAs compared to 781 in whites (p<0.05). Whites were more
likely to have eosinophils on biopsy compared with AAs (p=0.015). AAs with eosinophils on biopsy
had a greater likelihood of being diagnosed with eczema compared to both whites (p<0.0002) and
AAs without eosinophils on biopsy (p<0.005). Patients with blood eosinophilia were more likely to
have a previous diagnosis of eczema or psoriasis (p<0.04). Of these, 31% of AA men had previous
diagnosis of eczema compared with 15% of white men (p=0.042). Independent of race, blood
eosinophilia was predictive of more advanced disease (stage IIB versus stage IB (p<0.0001)), increased
number of treatment types (p<0.002) and less responsiveness to treatment (p<0.0006). The differ-
ences in age at diagnosis and previous diagnosis of eczema between races may highlight either a
disparity in MF diagnosis or a difference in pathophysiology. Similarly, the variation in average
maximum eosinophil count and presence of eosinophils on biopsy may highlight how eosinophils
in either blood or tissue represent an important distinction in the biology of MF between races. We
confirm that patients with eosinophilia present with more advanced disease, receive more treat-
ments and see fewer effects of treatments suggesting that eosinophilia may be a clue to a distinct
cytokine profile that portends a poorer prognosis.
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Type 1 Diabetes associated auto-antibodies are present in 19% of alopecia areata sera
L Petukhova,1,2 M Duvic,6 M Hordinsky,7 D Norris,8 V Price,9 A DeJong,1 L Bian,1 DL Pittman,10
WE Winter,10,11 J Mackay-Wiggan,1 R Clynes1,4,5 and AM Christiano1,3 1 Dermatology, Columbia
University, New York, NY, 2 Epidemiology, Columbia University, New York, NY, 3 Genetics &
Development, Columbia University, New York, NY, 4 Pathology, Columbia University, New
York, NY, 5 Medicine, Columbia University, New York, NY, 6 Dermatology, MD Anderson
Cancer Center, Houston, TX, 7 Dermatology, University of Minnesota, Minneapolis, MN, 8
Dermatology, University of Colorado, Denver, CO, 9 Dermatology, UCSF, San Francisco, CA,
10 Pathology, University of Florida, Gainesville, FL and 11 Pediatrics, University of Florida,
Gainesville, FL
Alopecia areata (AA) is diagnosed by clinical and histopathological findings, both of which are non-
quantitative and lack sufficient resolution to identify molecular subtypes of disease. Serum bio-
markers provide an efficient way to screen and assess disease activity and could additionally pro-
vide information to classify AA patients based on molecular characteristics. Our recent GWAS
identified genes that strongly align AA with type 1 diabetes (T1D), in support of the ‘Common Cause
Hypothesis’. We therefore sought to determine if there is analogous evidence in the sera of AA
patients by screening for circulating antibodies frequently found in T1D patients. AA serum (n=74)
obtained from the National Alopecia Areata Registry across the phenotypic spectrum of AA: tran-
sient (AAT); patchy (AAP); totalis (AT) and universalis (AU), was screened for antibodies against Islet
Cell Cytoplasmic Autoantibodies (ICA), Glutamic Acid Decarboxylase (GAD), and Insulinoma-Asso-
ciated-2 Autoantibodies that target protein tyrosine phosphatase (IA 2). Combined antibody titers
were increased in AU (n=6), AT (n=3), AAP (n=3) patients, and AAT (n=3) patients. This study shows
a higher prevalence of T1D associated antibodies among AA patients (19%) relative to both the
general population (<2%), as well as relatives of T1D probands (~4%), extending evidence for the
Common Cause Hypothesis from genetics to serology. These findings further suggest that T1D bio-
markers could be used for endophenotyping AA patients.
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Interactions between adiposity and genetic polymorphisms on the risk of psoriasis
W Li,1 J Han,1,2 M Zhang1 and A A. Qureshi1,2 1 Department of Dermatology, Brigham and
Women’s Hospital, Boston, MA and 2 Channing Laboratory, Department of Medicine,
Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
In this study, we investigated the effect modification by obesity measures on the association between
SNPs from published GWAS and risk of psoriasis. Our psoriasis GWAS dataset comprised 9,194
participants, including 337 individuals with psoriasis and 8,857 controls from six GWAS, nested
within the Nurses’ Health Study (NHS), NHS II, and Health Professionals’ Follow-up Study. We uti-
lized Illumina HumanHap550 array, Illumina HumanHap 610 Quad array, or Affymetrix 6.0 array
for genotyping. MACH v1.0.16 was used to impute more than 2.5 million SNPs with HapMap CEU
phase II data as the reference panel. Genotyped SNPs passing quality control procedures and imputed
SNPs with minor allele frequency >2.5% and imputation R2>0.3 in each study were included. Cli-
nician-diagnosed psoriasis was ascertained with high validity. Information on body mass index (BMI)
and measures of central obesity (waist circumference and waist-hip ratio, WHR) were obtained on
the main questionnaire. For stratified analyses, BMI was dichotomized at 25, based on World Health
Organization criteria. According to the median value in three cohorts, waist circumference was
dichotomized at 30 (women) and 36 inches (men), while WHR was dichotomized at 0.8 (women)
and 1.0 (men). We identified 44 SNPs from previous reports, while 41 were included in our dataset.
There were significant interactions between BMI and two SNPs in the IL12B (rs3212227) and IL23R
genes (rs7530511). Further analysis of these two SNPs indicated interactions between rs3212227
and waist circumference or WHR (Pint<0.05), but not for rs7530511. These observations were con-
firmed among participants without T2D or CHD. The interactions remained after simultaneously
adjusting for BMI as a continuous variable. In addition, we did not observe significant main effect
for rs7530511. The association between a polymorphism in IL12B and psoriasis risk may be mod-
ified by measures of overall and central adiposity.
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Arbitration of diagnoses for quality assurance in pathology is reproducible for major dis-
crepancies
J Ho Dermatology, University of Pittsburgh, Pittsburgh, PA
Diagnostic errors made by pathologists can cause significant harm to the patient, resulting in over
treatment, under treatment, or inappropriate treatment of a patient. Reported pathologist error rates
are highly variable, ranging from less than 1% to greater than 10% of diagnoses. This high degree
of variability is caused by several factors, including types of cases and pathologists, demographics
and training of pathologists, and the arbitration process. One important aspect of quality assurance
in pathologists’ diagnoses is determining if two sets of diagnoses, rendered by different patholo-
gists, are discrepant, and if so, whether or not the discrepancy in the diagnoses leads to harm. This
arbitration process requires that a set of guidelines to determine the presence of discrepancy, and
the degree of discrepancy, be applied by the arbitrator to judge the discrepancy. Arbitrating pathol-
ogists diagnoses is complicated, since pathologists report in free text, in different styles, and often
using different terminology. In this study, we gave three arbitrators in four different subspecialties
(dermatopathology, gastrointestinal pathology, breast/gynecological pathology, genitourinary pathol-
ogy) two sets of diagnoses rendered by two different pathologists on the same sets of slides. Each
of the arbitrators were pathologists trained in the subspecialty that they arbitrated. Arbitrators were
instructed to score a (0) for no discrepancy, (1) for minor discrepancies, and (2) for major discrep-
ancies using the same set of guidelines based on significance of harm to the patient. The der-
matopathology arbitrators were composed of 1 dermatology trained dermatopathologist and 2 pathol-
ogy trained dermatopathologists, and the perception of significance in treatments of two discrepant
diagnoses was markedly different based on residency training. Overall, agreement across arbitra-
tors, within and across subspecialties was highly variable for minor discrepancies, but was highly
reproducible for major discrepancies.
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Physician survey of dermatology quality reporting system in Colorado
JH Dunn,1 BT Alvarez,2 RG Gamble,1 RP Dellavalle1,2,3 and CA Dunnick1 1 Dermatology,
University of Colorado School of Medicine, Aurora, CO, 2 University of Colorado School of
Public Health, Aurora, CO and 3 Department of Veterans Affairs Medical Center, Denver, CO
In 2006, the Centers for Medicare and Medicaid Services (CMS) established what is now called the
Physician Quality Reporting System (PQRS) as part of an incentive payment process to improve
healthcare preventive practices. As of 2011, there were 240 measures but only three measures spe-
cific to dermatology. Specifically, the measures cover the management of melanoma patients with
respect to continuity of care, coordination of care, and overutilization of imaging studies for stage
01-A melanoma. To assess how the 2011 PQRS measures are used in Colorado, a survey was dis-
tributed at the 2011 Colorado Dermatological Society Meeting. Of the 120 physician attendees, 61
responded, yielding a response rate of 51%. 61% of respondents report PQRS measures in their
CMS claims, 59% use an electronic health record (EHR), and 82% use an E-Prescribing program.
Most physicians (62%) felt that reporting PQRS measures are worth the time and effort although the
majority felt that the monetary reimbursement is not adequate for the effort required. Compared
with results from 2010 (in press, JAAD), it appears that more physicians report PQRS measures and
utilize EHR and E-prescribing programs. This is significant because CMS will require mandatory
reporting of these measures in 2015. Respondents from the current survey commented that major
hurdles to reporting melanoma quality measures were the inability to report data through existing
EHR or billing systems since melanoma reporting requires a melanoma registry such as that pro-
vided by the AAD. In addition, smaller practices may not encounter a Medicare patient with a new
diagnosis of melanoma on an annual basis. The results suggest PQRS is viewed as important, but
structural improvements in the reporting system could improve compliance.
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Bartonella bacteremia detected in non-lesional skin with laser scanning confocal microscopy
P Velho,1 E Breitschwerdt,2 L Henke,1 S Nye,1 J Nugent,1 S Kavand1 and M Ericson1 1 University
of Minnesota, Minneapolis, MN and 2 North Carolina State, Raleigh, NC
The extent of Bartonella sp. infection remains underestimated. Bacteremia caused by Bartonella
spp. may be asymptomatic; blood donors are known to be infected. Infection can be fatal, espe-
cially in immunodeficient patients. Immunocompetent individuals are also at risk of chronic infec-
tion by this intra-erythrocytic and intra-endothelial agent. A large spectrum of clinical manifesta-
tions has been related to Bartonella spp. infection. One in 4 patients with non-specific symptoms
tested positive for Bartonella spp.. Neurologic symptoms have been reported in infected patients.
There are no gold-standard tests to confirm Bartonella sp. infection and false-negative results are
frequent even with multi-step molecular and microbiological techniques and serology. Thus, diag-
nosis of Bartonella spp. remains challenging warranting development of sensitive and reproducible
diagnostic methods. Multiple technologies must be used together to improve diagnostic sensitivity.
We report on an 18 year-old male with chronic neurological symptoms who tested positive for Bar-
tonella spp. infection by PCR, enrichment culture of blood and serum as well as serology on dif-
ferent dates. The primers targeting the 16S–23S intergenic transcribed spacer region, as previously
described by Breitschwerdt et al. (J Microbiol Meth 69:273) were used. A skin biopsy was acquired
from a non-lesional area of the patient’s calf. Bartonella henselae and other gram-negative bacte-
ria were detected in and around dermal vasculature in a multi-stained thick tissue sections using
laser scanning confocal microscopy (LSCM). Similar Immunoreactivity was detected in appendix
tissue following an appendectomy, thereby confirming chronic Bartonella spp. systemic infection.
Even in the absence of skin lesions, skin biopsies can be quickly, 4 days, analyzed using LSCM to
confirm Bartonella henselae or suggest Bartonella sp. infection in suspected patients.
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Psoriasis and risk of inflammatory bowel disease in US women
W Li,1 J Han,1,2,3 AT Chan2,4 and AA Qureshi1,2 1 Department of Dermatology, Brigham and
Women’s Hospital, Boston, MA, 2 Channing Laboratory,Department of Medicine, Brigham
and Women’s Hospital and Harvard Medical School, Boston, MA, 3 Department of
Epidemiology, Harvard School of Public Health, Boston, MA and 4 Gastrointestinal Unit,
Massachusetts General Hospital and Harvard Medical School, Boston, MA
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC) have
been reported in individuals with psoriasis. Genome-wide association studies have found suscep-
tible genes common to psoriasis and IBD. However, epidemiologic data evaluating the association
between psoriasis and CD or UC are sparse. We evaluated the association between psoriasis and
incident CD and UC among women in the United States. A total of 174,646 participants were
included from the Nurses’ Health Study (NHS) (1996-2008), and NHS II (1991-2005). Lifetime his-
tory of physician-diagnosed psoriasis was obtained by self-reported questionnaires and confirmed.
Data on incident CD or UC was obtained by self-reports and confirmed by medical record review.
A total of 187 incident cases of CD and 236 incident cases of UC occurred during follow-up. We
observed a significantly increased risk of CD associated with psoriasis among both cohorts; the mul-
tivariate-adjusted relative risk (RR) was 4.00 (95% confidence interval (CI): 1.73-9.29) for NHS and
3.84 (95% CI: 1.86-7.91) for NHS II. However, the association with UC was not significant (RR 1.91,
95% CI: 0.60-6.07 for NHS and RR 0.68, 95% CI: 0.17-2.76 for NHS II). Similarly, in a combined
analysis including both cohorts, psoriasis cases experienced a significantly increased risk of CD
(combined RR 3.91, 95% CI: 2.26-6.76), but not UC (combined RR 1.23, 95% CI: 0.46-3.33). The
association remained consistent in a sensitivity analysis of confirmed psoriasis, significant for CD
(RR 5.05, 95% CI: 2.80-9.10) but not for UC (RR 1.85, 95% CI: 0.73-4.71). Further, the risk of CD
was much higher for women with concomitant psoriasis and psoriatic arthritis. In this study, psori-
asis was an independent predictor for CD among women.
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High prevalence of psoriasis among patients presenting with inflammatory bowel disease
E Mihalis,1 J Han,2 S Friedman,3 PA Banks,3 M Hamilton,3 F Makrauer,3 J Levine3 and AA Qureshi2
1 Harvard Medical School, Boston, MA, 2 Dermatology, Brigham and Women’s Hospital,
Boston, MA and 3 Gastroenterology, Hepatology, & Endoscopy, Brigham and Women’s
Hospital, Boston, MA
Preliminary studies have suggested an association between psoriasis and inflammatory bowel dis-
ease (IBD), including Crohn’s Disease (CD) and ulcerative colitis (UC). Estimates of the prevalence
of psoriasis in patients with IBD vary from 0.8% to 11.2%. In this cross-sectional study, we char-
acterized the presence, type, and severity of psoriasis in a population of patients presenting to an
IBD center. We explored differences in demographics, smoking status, exposure to biologic thera-
pies, and medical diagnoses between IBD patients with and without psoriasis. We used the self-
administered Psoriasis Screening Tool (PST) to screen for undocumented psoriasis among IBD patients.
The PST is a validated, ten item questionnaire with a sensitivity of 98.2% and specificity of 97.3%
in detecting psoriasis. Demographic and other diagnostic data were collected through electronic
medical records. A total of 147 patients presenting to the Brigham and Women’s IBD clinic com-
pleted the PST. The PST identified psoriasis in 12.9% of all patients seen in the IBD clinic, 13.4%
with CD, and 12.9% with UC. Of these patients, the majority reported a combination of types of
psoriasis. The majority also reported that they currently had “only a few patches” of psoriasis. The
PST detected nine cases of psoriasis not documented in the patients’ charts and failed to identify
one case of inverse psoriasis noted in a patient’s chart. Of the variables tested, arthritis was more
prevalent in IBD patients with psoriasis than in those without psoriasis (p=0.03). The results of this
study indicate that the prevalence of psoriasis is four to six times higher in patients with IBD as
compared to the general population. The PST is a useful tool in identifying psoriasis in a popula-
tion of patients at an IBD clinic. Psoriasis in IBD patients is mild and may present as any subtype,
with features of plaque, scalp, and inverse psoriasis appearing most frequently.
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Juvenile Localized Scleroderma (jLS) is associated with a high degree of morbidity: Descrip-
tion of the jLS subgroup of the CARRAnet Registry
E Wu,2 E Rabinovich,2 K Torok,3 S Li4 and R Fuhlbrigge1 1 Children’s Hospital, Boston, MA, 2
Duke University Medical Center, Durham, NC, 3 Childrens Hospital of Pittsburgh, Pittsburgh,
PA and 4 Hackensack University Medical Center, Hackensack, NJ
We present data on the jLS cohort from the Childhood Arthritis and Rheumatology Research Alliance
(CARRAnet) registry, a North American longitudinal observational study of pediatric rheumatologic
disorders. Cross-sectional baseline analysis. Data were available on 182 children. 76% were female
and 89% Caucasian, of which 12% were Latino. Mean age at onset was 7.6 years, with an average
2 year delay to referral. Mean disease duration was 4.8 years. Linear scleroderma was noted in
55% (including 34 face/scalp LS). Features of activity (erythematous/violacious color, extension,
induration, and warmth), skin damage (subcutaneous atrophy, hyperpigmentation, dermal atrophy,
hypopigmentation, and hair loss) and musculoskeletal damage (muscle atrophy, joint contracture,
hemifacial atrophy, and limb shortening) were recorded. Positive ANA (52%) was the only consis-
tent laboratory or imaging abnormality identified. Mean visual analog scale (VAS) physician global
assessment of activity was 1.53 and mean CHAQ score was 0.17. Mean parent/subject VAS score
of overall well-being was 1.85 and pain was 1.27. Health related quality of life was reported as
excellent in 48. A worst ever and current ACR functional class > I was reported in 26% and 12.5%,
respectively. Subcutaneous and oral MTX and pulse and long term daily CS were the most com-
monly used medications, followed by mycophenolate mofetil. jLS is reported more frequently in
females and Caucasians, and linear scleroderma is the most common lesion subtype, in this pedi-
atric registry. There is significant morbidity with severe tissue damage documented in 38%, includ-
ing 25% reporting limitation in functional capacity and only 27% reporting an excellent health
related quality of life. The high degree of morbidity associated with jLS highlights the need for treat-
ment studies to define optimal care.
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National utilization patterns of Mohs Micrographic Surgery for malignant melanoma and
melanoma in situ
KV Viola,1 L Gonsalves,2 C Gross3 and R Turner1 1 Dermatology, Albert Einstein College of
Medicine, Bronx, NY, 2 Department of Public Health, The Connecticut Tumor Registry,
Hartford, CT and 3 The Robert Wood Johnson Clinical Scholars Program, Yale University
School of Medicine, New Haven, CT
Although Mohs Micrographic Surgery (MMS) for the treatment of melanoma is controversial, a greater
body of recent literature has demonstrated the optimal use of this surgical technique for melanoma
in situ (MIS) and specific conditions of malignant melanoma. We will identify current physician
practices through identification of national utilization trends of MMS as compared with other types
of surgical intervention for malignant melanoma and MIS. We performed a retrospective review of
patients receiving surgical intervention for melanoma from 2002 through 2008 utilizing the Sur-
veillance, Epidemiology and End Results (SEER) data base, representing 26% of the US population
with 18 SEER cancer registries throughout the country. There were 153,675 recorded cases of
melanoma treated with surgery from 2002 through 2008, of which 92,702 were malignant and
60,973 were MIS; the incidence of both melanoma types increased yearly. Four percent of MIS cases
and 2% of malignant melanoma diagnoses were treated with MMS. Age, race, poverty level, Bres-
low thickness, Clark level, lesion location and region of country were associated with surgical
treatment type (all p<0.001). The likelihood of receiving MMS increased if the patient was over 65
years, tumor Breslow thickness <1mm, and if the Clark level was I-III (OR= 1.78, 3.14, 3.06 respec-
tively). As poverty level increased, the likelihood of receiving MMS decreased (OR= 0.47). To our
knowledge, these findings are the first to examine national patterns of MMS utilization in compar-
ison to other treatment modalities for melanoma over time. Our goal is to better describe the treat-
ment outcomes of MMS in the management of MIS and malignant melanoma on a national level.
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Undergraduate student knowledge about sexually transmitted disease in Brazil
E Lazzarini,1 TA Caldas,1 EM Pereira1 and PE Velho1,2 1 University of Campinas, Campinas,
Brazil and 2 Dermatology, University of Minnesota, Minneapolis, MN
Sexually transmitted diseases (STDs) are increasing in number. They are underdiagnosed with high
socioeconomic costs. College and university students are one among the most exposed popula-
tions to STDs. Increasing student knowledge about STDs is a prevention strategy. Our goal was to
evaluate a subpopulation that is at greater risk of acquiring a STD. All undergraduate students from
the University of Campinas were offered the opportunity to answer a questionnaire and read about
STDs. Information about student demographics and knowledge on STDs was ascertained. Students
were also asked their opinion about on the research instrument. The questionnaires were analyzed
by using the EnqueteFacil® program for 1448 students (sampling error < 3%). An equal number of
males and females participated in this study and, over 50% of participants were 20-23 year-old.
One in five reported no sexual intercourse at all, 29% reported their first intercourse after begin-
ning undergraduation. The first sexual intercourse experience was between the ages of 16 and 18years
to 48% of them. One in three reported having had more than one partner in one year and 56%
reported they did not always use condom. Three in four did not know that having one STD increases
the risk of HIV by 10 times, 27% and 47% did not know respectively that hepatitis B can be a STD
and cervical cancer is considered to be a STD. More than 80% answered they had questions about
STDs and up to 57% wanted to have courses about STDs. Over 90% of participants noted they
learned something through the process of answering the questionnaire and reading the information
provided, 82% intended to read more about STDs after participating in this research project. We
conclude that these students were exposed to STDs but in large part knew very little about these
diseases. Through the questionnaire and information provided, students increased their knowledge
about STDs. This approach has the potential to be a useful teaching instrument at other colleges
and universities throughout the world.
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Clinical characteristics and outcomes of Merkel cell carcinomas in the Kaiser Permanente
Northern California population
MM Asgari,1 E Warton,1 MM Sokil,1 J Iyer,2 KG Paulson2 and P Nghiem2 1 Division of Research,
Kaiser Permanente Northern California, Oakland, CA and 2 University of Washington, Seattle,
WA
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with high rates of recurrence and
mortality. Given its rarity, most published studies are based on data from tertiary cancer centers and
are not population-based. We sought to characterize all members diagnosed with MCC since 1995
from the Cancer Registry of Kaiser Permanente Northern California, a large, diverse community-
based health-maintenance organization. We aimed to describe the cohort and identify factors pre-
dictive of disease recurrence and survival. We identified 190 patients with MCC diagnosed between
January 1, 1995 and December 31, 2009. Patients were collectively followed for 735 person-years;
median follow-up was 7.4 years in living patients. MCC patients tended to be elderly (mean age
74.3, SD 12.2) Caucasian (n=181, 95.3%) males (n=119, 62.4%). Tumors mostly arose on sun-
exposed areas (head, neck and upper limb, n= 130, 68.4%). In unadjusted models, older age at
diagnosis (age >71 years) and higher tumor stage were associated with worse survival. Among
patients who experienced a recurrence, the median time to recurrence was 8.5 months after diag-
nosis, and 90% of recurrences occurred within 3 years of diagnosis. Patients with local or nodal
disease at presentation who received adjuvant radiation therapy were significantly less likely to
experience loco-regional relapse than those who did not receive adjuvant radiation (15% versus
40% at 3 years; p<0.01). Among patients with nodal disease, adjuvant chemotherapy was not asso-
ciated with significant improvement in overall survival. We conclude that consideration should be
given to adjuvant treatment with radiation for most MCC tumors to improve loco-regional control,
and that current chemotherapy regimens appear to be ineffective in substantially improving sur-
vival.
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